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Abstract 
 
Legal Defensiveness-Induced Life-Sustaining Treatment: 
Results of a Natural Experiment 
 
Background: Although great attention has been paid to futile life-sustaining 
treatment (LST), little is known as to whether decreasing a physician’s legal 
defensiveness could decrease LST. Focusing on the legally defensive attitude 
toward forgoing LST, whether a decrease in a physician’s legal defensiveness 
could decrease the use of legally high-risk LST was examined through 
quasi-experimental quantitative analyses under the natural experimental 
circumstances brought about by two landmark court decisions.  
 
Materials and Methods: After reviewing previous studies regarding 
defensiveness medicine and legal defensiveness, a conceptual framework for a 
legal defensiveness model was developed for this study and from the model, the 
study design for quantitative analyses was drawn. This study used the National 
Health Insurance Service Elderly Cohort (NHIS-NSEC) which consisted of 
588,147 Korean participants older than 60 years in 2002. From the NHIS-NSEC, 
73,096 decedents who died during 2003–2013 owing to cancer, circulatory, or 
respiratory diseases were selected as study subjects. Time series were constructed 
by time units of a quarter from 2003 to 2013 and divided into periods of 
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increasing, conflicting, and relieving periods according to the level of physicians’ 
legal defensiveness toward forgoing LST. Within the time series, trends and 
changes in legally high-risk (physician-driven) LST including cardiopulmonary 
resuscitation (CPR) and mechanical ventilation (MV) provided during the last 30 
days of life were measured and compared between three periods by interrupted 
time series with segmented regression. Admission to hospitals and per capita 
hospital days were used as control outcomes (patient-driven) for comparison. 
Annual increasing rate (AIR) of outcomes during each period and ratio of AIR 
and outcome level along with 95% confidence intervals were estimated with a 
generalized linear model with a Poisson distribution and robust standard error.  
 
Results: During the study period, CPR and MV were administered to 7,809 
(11.1%) and 11,863 (16.8%) decedents, respectively, during their last 30 days of 
life. The risk of receiving CPR during the last 30 days of life increased 11.9% per 
year (AIR 1.119, 95% CI 1.082–1.158), decreased 6.1% per year (AIR 0.939, 95% 
CI 0.899–0.981), and maintained the same level (RR 1.009, 95% CI 0.982–1.038) 
during the periods of increasing, conflicting, and relieving legal defensiveness, 
respectively. The risk of receiving MV during the last 30 days of life increased 8.3% 
per year (AIR 1.083, 95% CI 1.055–1.112) during the increasing period of legal 
defensiveness, then maintained the same level during the conflicting (AIR 1.017, 
95% CI 0.982–1.053) and relieving (AIR 1.000, 95% CI 0.978–1.022) periods of 
iii 
 
legal defensiveness. In contrast, although AIRs during the conflicting and 
relieving period were lower than the AIR of the increasing period, the risks of 
admission to hospitals (12.3%, 3.6%, and 1.1% per year) and per capita hospital 
days (20.5%, 4.9%, and 2.3% per year) increased during all three periods. 
 
Conclusion: This study provides evidence that physicians’ legal defensiveness 
toward forgoing LST contributes to administering LST and if a physician’s legal 
defensiveness can be decreased then defensive LST can also be decreased. 
However, considerable legal defensiveness still remains and the level of LST 
needs to be decreased further. Policies that can reduce physician’s legal 
instabilities should be implemented to reduce defensive LST. 
 
 
 
 
 
 
 
 
 
 
Key words: Life-sustaining treatment, Death with dignity, Euthanasia, Legal 
instability, Legal defensiveness 
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I. Introduction 
 
1. Study Background 
 
In February 3, 2016, the Hospice-Palliative Care and Decision on 
Life-sustaining Treatment Care of Dying Patients Act (hereinafter referred to as 
“the LST Act”) was enacted and its enforcement begins on August 4, 20171. The 
LST Act permits the removal of only extraordinary treatments such as CPR 
(cardiopulmonary resuscitation), MV (mechanical ventilation), hemodialysis, and 
chemotherapeutic treatment and applies only to patients expected to die soon. 
However, it has significant implications for physicians as well as the general 
public in that the LST Act is the first legislation about the legality of forgoing life-
sustaining treatment (LST) in South Korea. However, because the LST Act does 
not describe how to determine the legality of discontinuing LST when a patient 
has not reached the irrecoverable and imminent death stage, the right to refuse 
unwanted treatment is not guaranteed sufficiently.  
Before the LST Act, there was no specific law governing forgoing LST in South 
Korea and hence there has been considerable uncertainty concerning the 
permission of removal of life-sustaining devices and punishments for such acts2-4. 
In the meantime, two landmark judicial judgments regarding removal of MV from 
incompetent patients affected physicians’ attitudes toward forgoing LST. The LST 
Act was enacted under the influence of judicial judgment and associated public 
debate.  
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This situation is very similar to the process of the enactment of the Patient Self 
Determination Act in the USA.2,4 Physicians’ paternalistic decision-making 
changed considerably following the 1976 groundbreaking case of Karen Ann 
Quinlan, when the New Jersey Supreme Court announced that a patient’s guardian 
had the right to refuse unwanted LST even if doing so resulted in death5,6. In the 
1990 Nancy Cruzan case, the USA Supreme Court declared a patient’s 
comprehensive right to refuse unwanted treatments including LST5,6. Following 
the Nancy Cruzan case, the Patient Self Determination Act was passed in 1990 to 
protect a patient’s right to refuse unwanted LST7. 
Although higher spending in the last year of life might not improve quality of 
end-of-life care8, the intensity of end-of-life care has been high and increasing 
worldwide9-13. Many researchers have reported the aggressiveness of end-of-life 
care in western countries and South Korea9-11,13-18. However, there are substantial 
discrepancies between patient’s desires and clinical practice. People do not want 
LST but physicians perform LST. A study of 3,840 Korean individuals showed 
that most of the general public and physicians supported withdrawal of futile 
life-sustaining treatment (87.1%–94.0%) and the use of active pain control 
(89.0%–98.4%). A slightly smaller majority (60.8%–76.0%) supported 
withholding life-sustaining treatment 19.  
In 2007, Korean dying patients in the ICU received LST including CPR (19.0–
30.9%) and MV (42.9–61.5%)20 during their last 30 days of life. In western 
countries, many dying patients utilize medical services within the last 30 days of 
life, including hospitalization in acute care hospitals (44.8–62.6%) and ICU 
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admission (3.5–27.2%)18. 
It is not a general phenomenon that people determine their way of death and 
express their wishes about that decision. Advance directives or POLST (physician 
order for life-sustaining treatment) have not been satisfactorily used in western 
countries where the right to self-determine whether to receive LST was 
recognized socially several decades ago21,22. Several surveys done in previous 
studies showed completion rates of advance directives are only around 30%23,24. 
Although advance directives could decrease medically futile LST, it is hard to 
expect patients to provide such advance directives in South Korea25. In the 
absence of advance directives, physicians usually have no choice but to administer 
LST such as CPR and MV during medically urgent states. Among many reasons 
for providing LST, physicians’ fear of legal liability stemming from legal 
uncertainty might play a pivotal role in South Korea. 
In spite of the importance of physician’s legal defensiveness toward forgoing 
LST, there is limited literature investigating whether LST-related decisions of 
physicians could be affected by perceived legal defensiveness. Furthermore, the 
few quantitative analyses using nationally representative administrative claims 
data were conducted in mainly western countries. Therefore, there is little 
evidence of whether physician’s legal defensiveness could affect LST-related 
decisions in East Asian countries. 
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2. Study Objectives 
 
Under the peculiar legal circumstances regarding LST in South Korea, this 
study investigated physicians’ defensive attitude toward forgoing LST through 
quantitative analyses measuring specific procedures or medical utilizations. This 
study takes the attitude that a patient has the right of self-determination to refuse 
medically futile LST based on human dignity and the right to pursue happiness as 
a human being under Article 10 of the Constitution26. Just as physician-assisted 
suicide is illegal in most states in the USA27, the right to die actively is not 
currently legal in South Korea in 201628. Even if a dying patient has the 
constitutional right to refuse LST and the result of refusal is death, the right to 
refuse LST and the right to die are not synonyms29. The Korean Supreme Court 
and the LST Act did not say anything about the right to die just as in the Quinlan 
and the Cruzan cases28,29. Forgoing LST in this study is limited to the exercise of 
the right to refuse unwanted treatments.  
Therefore, the principal purpose of this study was to investigate whether 
physician’s legal defensiveness could affect LST-related decisions. To achieve the 
principal purpose, trends of legally high-risk outcomes and control outcomes were 
measured and compared between periods of physicians’ legal defensiveness. 
Additionally, a detailed analysis of data was performed to present descriptions of 
the level of LSTs in time series divided by periods of legal defensiveness. 
Focusing on the physician’s legal defensiveness toward forgoing LST, specific 
hypotheses were examined: 
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First, LSTs would decrease if physicians’ legal defensiveness was decreased. 
Second, physician-driven legally high-risk LSTs could be decreased earlier than 
patient-driven medical utilization. 
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Ⅱ. Theoretical Background 
 
1. Two Landmark Court Decisions regarding LST 
 
In the absence of a specific law to govern LST directly in South Korea, criminal 
law that punishes murder and murder upon request could be applied to physicians 
who terminate LST after a family’s request3. Until 1998, there had been no 
judicial precedence that ruled whether withdrawal or withholding of LST was 
legal or illegal. However, Korean medical society has perceived that physicians in 
South Korea perform clinical practice in a context of legal ambiguity and under 
the fear of prosecution, even if what they do what is considered routine practice in 
many other countries worldwide3. Meanwhile, there were two important legal 
cases related to the legality of forgoing LST. One was a criminal case and the 
other was a civil case. Although the underlying facts and legal judgment were 
different from each other, withdrawing MV from incompetent patients at the 
request of family members was the starting point of both cases. In addition, the 
impact of the rulings on medical and legal community was so powerful that 
physicians and lawyers are quite familiar with them30,31. The following describes 
the two cases, focusing on facts related to the doctor's legal uncertainty. 
 
(1) The Boramae Hospital case 
 
On December 4, 1997, a 58-year-old man developed an epidural hemorrhage in 
his house after falling while drunk. Admitted to the Boramae hospital, he was 
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transferred to the ICU after surgery. Because his spontaneous respiration was 
insufficient, he depended on MV. The next day, the patient, who had no response 
after surgery, returned to positive light reflex, Glasgow Coma Scale E3 and M5. 
The wife insisted several times on the discharge of the patient for economic 
reasons, as there were ongoing medical costs for continued treatment. In addition, 
the patient was an unemployed alcohol abuser and perpetrator of family violence. 
The physicians tried to persuade the wife to not discharge the patient because of 
the possibility that he would die. Furthermore, they recommended she seek a safe 
refuge until the state of the patient could be stabilized. Because she did not accept 
this recommendation and persisted discharge of the patient, the physician in 
charge decided to permit discharge. Two days after the surgery, the patient was 
discharged to home and intubation tube was removed. The patient died within five 
minutes after removal of the intubation tube. On May 15, 1998, a lower court 
sentenced two physicians with murder32. In February 7, 2002, the Seoul High 
Court, an appellate court, sentenced them with aiding and abetting murder33. In 
June 24, 2004, the Korean Supreme Court concluded that the doctors’ action that 
allowed the patient to be discharged from hospital led to the patient’s death and 
rejected a final appeal and the decision of the Seoul High Court was upheld34. The 
physicians were declared murderers by the court. 
The impact of this case was so great that even before the Supreme Court ruling 
came out, legal research papers were published based on the lower courts’ 
decisions35-37. A well-known criminal law professor pointed out that the reaction 
of the medical community to the ruling was at the level of astonishment and they 
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expressed a reluctance to describe the physician’s actions as murder38.  
In a survey study done in 1998, 100% of physicians were aware of the Boramae 
hospital case, and 98% of them considered the ruling to be unfair30. The medical 
profession’s emphasis on the unfairness of the decision by pointing out the reality 
of the clinical setting was ignored31. In particular, physicians raised questions 
about the basis of the fact-finding by the court, especially the possibility of the 
patient’s recovery, which was the critical issue of the case31. 
Before the Boramae Hospital Case, the topic of end-of-life medical decisions 
had been rarely discussed in Korea. However, after the Boramae Hospital Case in 
1997, the issues surrounding end-of-life medical decisions have received the keen 
interest of the general public3.  
This legal case was not a case of withdrawal of LST but rather a case of 
discharge against medical advice (DAMA)39,40. The patient’s surrogate decision 
maker, his wife, did not have any intention to act in his best interest4. There was 
no mention of the patient’s explicit or presumptive willingness to forgoing LST. 
Before this case, physicians had often performed the withdrawal of futile LST for 
terminally ill patients and allowed for hopeless discharge31,40,41. However, after 
this verdict, the majority of Korean medical society somewhat misunderstood that 
this case was about euthanasia or a hopeless discharge, which has been routinely 
done before3,30,42. 
After this judgment, medical professionals have generally interpreted that not 
only DAMA but also withdrawal of life-sustaining treatments for a terminally ill 
patient could be regarded as homicide2,3,40. The Boramae Hospital case made 
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physicians worry about being convicted of murder4. Since then, they have taken a 
defensive attitude towards treating terminally ill patients and they have displayed 
a tendency to continue futile, often excessive, treatments41. Physicians have kept 
their patients alive for a long time even though they knew that medical treatments 
for their patients were futile and useless3. 
 
(2) The Grandma Kim case  
 
In February 16, 2008, while undergoing an endoscopic lung examination for 
pneumonia at Severance Hospital in Seoul, a 76-year-old patient, Grandma Kim, 
sustained massive hemorrhage and hypoxic brain damage, leaving her in a 
persistent vegetative state and dependent on a MV2. In the absence of advance 
directives, the family members applied a provisional disposition on March 5, 2008 
and filed a lawsuit on June 2, 2008. The family members wanted to not provide 
any medical treatment for her, including MV, medication, nutrition, hydration, and 
CPR42. During the trial, the plaintiff accepted the court’s proposal to limiting the 
claims to not providing MV42. During the trial, several doctors testified that Ms. 
Kim had no reasonable chance of recovering from her vegetative state. The 
patient’s children testified that their mother had always opposed keeping people 
alive when there was no hope of recovery. In November 28, 2008, the Seoul West 
District Court concluded that there was no hope for recovery and her inferred 
intention not to receive LST was assumed, and ruled that removing the MV was 
allowed43. This was the first court judgment that allowed the withdrawal of LST. 
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In February 10, 2009, the Seoul High Court upheld the decision of the trial court44. 
In May 22, 2009, the Korean Supreme Court upheld the appellate court ruling26. 
As the first court decision regarding legal and bioethical issues relevant to LST 
in South Korea, there are several meaningful points to discuss2,4. For the first time, 
the Supreme Court declared a constitutional right to refuse LST and provided 
requirements for withdrawal of LST. The Supreme Court said “LSTs carried out in 
cases where a patient has no medical possibility of recovering consciousness, has 
lost critical biological function, or has only a short time to live (hereinafter “the 
irrecoverable stage of death”) are not aimed at improving the patient’s condition, 
but merely at maintaining the patient’s current condition26. Because in such an 
exceptional circumstance futile LST “can harm the patient’s human dignity and 
fundamental value as a human being”26, “protecting the patient’s dignity, value, 
and right to pursue happiness as a human being is consistent with social norms, 
and respecting the patient’s decision to face death does not go against the 
constitutional spirit”26. Related to procedural requirements, the Supreme Court 
recommended that “Unless the patient files a lawsuit directly in court, it is 
desirable for a committee composed of medical doctors, etc. to decide whether the 
patient has reached an irrecoverable stage of death”26. 
Legal uncertainty about decision making around LST was addressed in a 
statement of grounds in the final civil appeal2,42. The defendant appealed that a 
general substantive and procedural guideline for forgoing LST is crucial and it is 
impossible for all cases to rely on a court’s decision. As for uncertainty about 
medical futileness, it often cannot be predicted with certainty that the patient has 
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entered into an irrecoverable death stage. Decisions on whether the patient entered 
into an irrecoverable death stage is a very complicated process involving 
considerable uncertainty intrinsic to medical decision making3. This is further 
corroborated by the fact that Grandma Kim survived an additional 6 months after 
removal of the MV.  
Although the Supreme Court limited the range of patients for whom forgoing 
LST is allowed, this ruling allowed physicians to recognize that forgoing LST is 
not illegal and they would not be prosecuted as murders. However, the general 
guideline composed of broad and ambiguous substantive requirements and 
insufficient procedural requirements could not eliminate the risk of legal disputes 
and physicians’ defensive attitudes towards forgoing LST42.  
 
2. Physicians’ Psychological Burden of Legal Dispute  
 
Physicians' legal liability related to forgoing LST is realized by civil liability 
for damages, involuntary manslaughter in criminal law, and licensure punishment 
by regulatory sanction. Because forgoing LST means physical death, in extreme 
cases criminal prosecutions charging homicide could be initiated34,45. In the course 
of long-lasting litigation and trials, physicians incur damages to their professional 
reputation, criticism from family members, and experience considerable physical 
and psychological burdens regardless of the results of legal judgment45,46. For 
some physicians, these burdens may be as large as their concern about winning or 
losing a case45. 
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In the first legal case, the Grandma Kim case, permitting withdrawal of LST in 
South Korea, the concurrence of the majority opinion in the en banc decision of 
the Korean Supreme Court demonstrated incomplete resolution of legal 
uncertainty precisely and appropriately26. The concurrence opinion worried about 
the effectiveness of the judgment permitting withdrawal of LST and expressed 
their view concerning appropriate legal procedures for determining whether 
discontinuing LST can be permitted as follows26: 
“Where a patient who has already reached the irrecoverable stage of death 
without issuing a prior medical instruction, there are two possibilities as to 
discontinuing life-sustaining treatment: (i) The patient seeks to discontinue 
life-sustaining treatment and the medical practitioner infers that the patient would 
consent to discontinue treatment since the patient has reached the irrecoverable 
stage of death as determined by a committee composed of expert doctors, etc. … 
In case (i), the medical practitioner can discontinue life-sustaining treatment by 
accepting the patient’s request after going through procedures and considering 
expert opinions as stated in the Majority. Thus, interference by a court is likely 
unnecessary when the patient’s request clearly satisfies the element for 
discontinuing life-sustaining treatment. However, the problem is that the medical 
practitioner, even in case of (i), cannot be completely immune from legal liability 
regarding the discontinuance of life-sustaining treatment. Since no legislation has 
been enacted stipulating the legal procedure governing the discontinuation of life-
sustaining treatment, to exempt the medical practitioner from responsibility solely 
because the medical practitioner performed such treatment based on careful 
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procedure leads to the issue of protecting the patient’s right to life being left 
entirely to the medical practitioner. Consequently, even though the medical 
practitioner discontinued life-sustaining treatment after going through necessary 
procedures, we cannot exclude the possibility that the medical practitioner may 
face civil and criminal liability because it may subsequently be determined that 
the patient had not reached the irrecoverable stage of death or that the patient’s 
inferred intent was unclear. As the possibility of criminal liability based on ex post 
facto judicial evaluation cannot be excluded, the medical practitioner cannot help 
but adopt a defensive attitude towards the patient’s request, and if there is any 
doubt, he/she would hesitate to discontinue life-sustaining treatment. In this 
context, it is understandable that the medical profession is currently taking a 
passive approach towards discontinuing life-sustaining treatment despite the 
patient’s request. Furthermore, the uncertainty as to the possibility of legal 
liability based on decision after the fact cannot be fundamentally alleviated by 
suggesting substantial elements without procedural elements established. Thus, 
allowing case (i) to also go through a procedure to obtain the court’s decision 
would considerably help in stabilizing legal relations concerning the 
discontinuance of life-sustaining treatment.” 
It is difficult for a physician to accurately determine whether a patient has 
entered an unrecoverable death stage, and it is even more difficult to determine 
the presumptive willingness of a dying patient regarding LST unless there is a 
living will. Furthermore, in addition to the patient factors, physicians should 
consider not only the relationship and consistency of the decision made by the 
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family members but also underlying legal problems surrounding family members 
such as the inheritance. Decision making for LST needs substantial effort and time 
and since the consequence of the decision is death of a patient, substantial 
psychological burden is imposed on physicians in practice. Even if a physician’s 
decision was completely legal, it does not eliminate the risk of getting involved in 
a litigation process. Even if the decision is proven to be free from legal liability by 
ex post court judgment, physical and psychological burdens during the course of 
the proceedings are inevitable. 
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3. Defensive Medicine 
 
Legal instability and legal defensiveness have been described as defensive 
medicine in the medical and economic literature for many years. Previous studies 
suggested that the majority of adverse clinical events do not result in malpractice 
claims, and a substantial proportion of claims involve no medical error, both of 
which suggest substantial idiosyncrasy in malpractice47-49. The primary 
determinant of whether an injury will receive compensation is not the extent of 
negligence but the extent of the injury49,50. For LST-related decisions, the injury is 
death, the most serious adverse event. In addition, empirical evidence suggests 
that the incentives produced by the tort-based legal system for malpractice claims 
leads doctors to practice defensive medicine—to administer precautionary 
treatment with minimal expected medical benefit out of fear of legal liability50-53. 
Defined as medical practice based on fear of legal liability rather than on 
patients' best interests, the concept of defensive medicine describes physicians' 
distorted behaviors in response to potential threats stemming from malpractice 
litigation46,54,55. In other words, defensive medicine can be defined as medical 
practice decisions predicated on a desire to avoid malpractice liability, rather than 
a consideration of medical risk-benefit analysis50. Explanations for physicians' 
defensive behaviors, however, vary54. Many studies, especially those based in the 
US context, attribute defensive medicine to medical malpractice litigation systems 
whereas others have sought to explain it from physicians' internal emotional 
mechanisms rather than from external modifiers of behaviors54. In addition to the 
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economic burden of legal disputes, the likelihood of a claim that takes many years 
to resolve or that involves a large amount of conflict or hassle has a substantial 
effect on defensive treatment behavior52,56.  
Physicians report defensive medicine as a major contributor to healthcare costs, 
and commonly argue that they must practice defensively to reduce malpractice 
liability48. For instance, among physicians practicing in high risk specialties in 
Pennsylvania during a malpractice crisis, more than 90% reported sometimes or 
often practicing defensive medicine48,56. These assurance behaviors of physicians 
can also be found in a study that reported that within specialty and after 
adjustment for patient characteristics, higher resource use by physicians is 
associated with fewer malpractice claims48. 
In a simple model of medical decision-making, the legal system would induce 
doctors and patients to balance the costs of liability against the costs of 
precautions and the health benefits of care46. Unfortunately, operation of the 
countries’ health-care and liability systems deviates substantially from this simple 
model46. In practice, however, these systems can lead doctors to take insufficient 
precautions against medical injuries, or might lead to defensive medicine46. 
The practice of defensive medicine can take two forms: positive and negative46. 
Positive defensive medicine, also called assurance behavior, includes the supply 
of care that is unproductive for patients; negative defensive medicine, also called 
avoidance behavior, takes place when providers decline to supply care that is 
productive for patients46,56. In other words, positive defensive medicine is 
expressed by an increased use of resources, both to reduce the risk of receiving a 
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further complaint and to increase doctors’ ability to defend one, and negative 
defensive medicine refers to withdrawal of medical services. Doctors may cease 
providing care if they believe particular types of patients or diseases place them at 
greater risk of receiving a complaint57.  
Positive defensive medicine can arise from two sources46. First, because doctors 
bear substantial uninsured, non-monetary costs of liability, including the value of 
lost time, the matter of reputational damage, and the expenditure of emotional 
energy in responding to a malpractice claim, they might view the cost of 
negligence to be greater than the burden that negligence imposes on patients46. 
Second, because neither patients nor doctors bear the full cost of care in any 
particular case, they might perceive the cost of precautions to be less than it 
actually is. Even if tort law allocated the burden of medical injuries perfectly and 
inexpensively, the fact that the costs of precautionary services are largely financed 
through health insurance or government reimbursement can lead doctors and their 
patients to take socially excessive care against injuries46.  
Negative defensive medicine also can arise from two sources. The same 
uninsured non-monetary costs of liability that create the incentive for positive 
defensive medicine can also drive doctors out of practice. Furthermore, to the 
extent patients reap substantial surplus from medical care for which they cannot 
compensate providers, doctors might weigh the malpractice downside of a course 
of care against only a fraction of the upside, leading them to withhold treatments 
that can be in their patients’ best interests46. 
The fact that physicians tend to have defensive attitudes against certain types of 
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medical services is well known in western countries and South Korea56,58-60. 
Previous empirical evidence suggests that patients from areas with the greatest 
malpractice pressure experience more defensive medical practice46,50,61,62. In a 
series of studies, Kessler and McClellan used longitudinal data for almost all 
elderly patients admitted to hospital with serious cardiac illness, matched with 
information on the existence of law reforms from the US state in which the patient 
was treated. They reported that reforms that directly limited liability—such as 
caps on damages—reduced hospital expenditures by 5–9% in the late 1980s, with 
effects that are greater for ischemic heart disease than for acute myocardial 
infarction patients. In contrast, reforms that limit liability only indirectly were not 
associated with any substantial expenditure effects. Thus, treatment of elderly 
patients with heart disease does include defensive medical practices, and 
reductions in liability can reduce this costly behavior 52,63. Although the effect size 
was small, the presence of defensive medicine among physicians was supported 
by data suggesting the rate of childbirth by cesarean section has increased due to 
defensive medicine against malpractice disputes regarding childbirth64. 
Findings of two studies in the USA identified the mechanism by which direct 
reforms affect doctors’ behavior, to help predict whether new and untried types of 
reforms will have similar effects. Kessler and McClellan reported that although 
reforms directly limiting liability improve medical productivity mainly by 
reducing malpractice claims rates and compensation conditional on a claim, other 
policies that reduce the time spent and the amount of conflict associated in 
defending against a claim can also reduce defensive practices substantially53. In 
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addition, the level of malpractice pressure may be too high or misdirected, leading 
doctors to take socially excessive precautions, such that the marginal social 
benefit of the additional treatments provided are greater than their marginal social 
cost. In this case, malpractice pressure would induce doctors to practice defensive 
medicine50. 
Reforms in tort law are designed to influence patient decisions about bringing 
and resolving liability claims. In turn, law reforms may affect the incentives the 
liability system gives to health care providers to undertake precautionary care or 
malpractice pressure50. The authors of one article, taking a legal and psychological 
basis, argued that a shame response from malpractice drives the observable 
changes in physicians’ attitudes towards patients and changes in practicing 
behavior57. Research from the USA, the UK, and Australia indicate that positive 
defensive medicine such as increased referrals, test ordering, and prescribing are 
all responses to litigation. These common findings from disparate cultures (with 
respect to complaint and litigation procedures) suggest that doctors’ responses 
arise more from internalized mechanisms, rather than from an externalized 
modifier of behavior65. 
Although the direct costs of lawsuits and settlements account for a very small 
fraction of total health spending—in the USA, less than 1%—the costs of 
defensive medicine might be far greater. Almost one in four healthcare dollars is 
spent on legally, not medically-indicated medicine, in the USA66. 
Because doctors might not take into account all of the costs and benefits of 
treatment decisions, small increases in the costs of lawsuits might lead to large 
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changes in the intensity and volume of care46,55.  
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4. Legal Defensiveness 
 
Defensive medicine in the medical literature represents only part of a complex 
constellation of factors that comprise physicians' reluctance to terminate treatment. 
This phenomenon encompasses medical, ethical, legal, social, psychological, and 
spiritual factors interacting in ways that are not fully understood. For the purposes 
of this study, however, we have chosen to focus on the legal and psychological 
aspects of physicians' reluctance to terminate treatment and the corresponding 
ethical implications67. For integration of factors associated with physicians’ 
perceived legal risk about LST-related decisions, McCrary and Swanson proposed 
the concept of legal defensiveness with tools for measuring the intensity of legal 
defensiveness67. They defined legal defensiveness as the aggregate of legal factors 
encompassing physicians' perceptions and practices regarding the abatement of 
life-sustaining treatment. Thus, legal defensiveness includes physicians' reported 
practice of defensive medicine, but the phrase also includes physicians' attitudes 
and perceptions about potential civil and criminal liability, physicians' perceptions 
of a general obligation to continue prescribing life-sustaining treatments, and 
physicians' responses to multi-factorial hypothetical cases containing legal 
issues67. 
Based on evidence from their pioneering studies, McCrary and Swanson 
suggested phenomena regarding physician’s legal defensiveness: 1) a significant 
proportion of physicians manifest extreme legal defensiveness surrounding 
end-of-life treatment; 2) inaccurate information often circulates among physicians 
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regarding their risk of litigation and/or prosecution for terminating LST; 3) 
physicians’ exaggerated concerns about their legal risk can infuse unnecessary 
conflict into relationships between physicians, terminally-ill patients, and/or their 
surrogate decision makers; and 4) better knowledge of relevant medical law might 
correct misinformation and mitigate these attitudes held by some physicians67-69.  
Physicians who use other physicians as a source of knowledge of laws 
regarding withdrawal of treatment performed significantly worse on the legal 
knowledge instrument than their colleagues who do not rely on physicians for 
such information. This suggests that many physicians currently obtain much of 
their information on the law from a clearly inappropriate source—other physicians 
also lacking sufficient knowledge67. If physicians make treatment decisions for 
dying patients primarily in reliance on perceived constraints from the legal system, 
then incorrect information about the law may have severe consequences for 
patients-most likely in the form of overtreatment67. The intensity of legal 
defensiveness could be affected by physician factors such as specialty and clinical 
experience67. For example, legal defensiveness tends to be high among 
non-oncologists and less-experienced physicians67. 
Legal defensiveness among South Korean physicians was reported consistently 
in several studies. In 2011, a survey of Korean critical care medicine specialists 
revealed that the biggest obstacle to the application of the guidelines was the lack 
of legal support60. The preferred method for dispute resolution when there is a 
dispute about forgoing LST could provide evidence of legal defensiveness. A 
study in 2009 to sample the public consensus on foregoing of LST found that 75% 
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of the general population wanted to resolve dispute with physicians directly, while 
55% of physicians preferred to resolve disputes by way of the hospital ethics 
committee and only 34% wanted direct resolution with the patient side20. In other 
studies, physicians reported that legal risk is a major barrier to forego LST70 and 
the Korean Supreme Court recognized physicians’ hesitation to withdraw LST26. 
Due to the fear of legal disputes, physicians highly preferred to resolve LST-
related disputes with the aid of the hospital ethics committee70. 
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Ⅲ. Conceptual Framework of Legal Defensiveness Model 
 
1. The need for a legal defensiveness model 
 
There is scarce literature suggesting a comprehensive model or conceptual 
framework for LST-related decision making. Although not focusing on the 
decision making process, one study proposed a conceptual framework to guide 
research and policy aimed at enhancing healthcare efficiency and promoting 
goal-directed care of patients with serious illnesses. Kelley et al. proposed a 
model that provides a conceptual framework for more inclusive and 
comprehensive studies by describing the simultaneous interactions and effects of 
region, physician, patient, and family determinants on treatment intensity8. 
Kelley’s model consists of patient and family determinants, and region and 
physician determinants. After a rigorous literature review, the authors included 
factors influencing treatment intensity for patients with serious illness. Although 
the authors indicated that significant interactions between constructs might exist, 
legal aspects were not considered in the model. Among the constructs, although 
the individual physician practice pattern could be affected by perceived legal 
instability, the authors did not include perceived legal instability as extrinsic or 
intrinsic characteristics of physicians. Only decisions on medical futileness were 
considered as a benefit from treatment that composed patient and family 
determinants. 
However, as described in explanations for defensive medicine, legal 
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defensiveness as an extrinsic factor plays a key role in decision making as to 
whether to perform LST67,69. There is a significant difference between the present 
laws about LST and the actual practice of physicians. A major explanation for the 
persistent gap between medical-legal principle and the reality of medical practice 
is ignorance and misunderstanding of the law. Liability is on the minds of 
physicians, who tend to overestimate the risk of malpractice lawsuits27,47. In the 
clinical setting "myths about the law often overshadow reality"71. The most 
efficacious social facts in the actual hospital situation are physicians’ perceptions 
about themselves, not the objective risks72. Often, clinicians' perceptions are that 
legal risks are far greater than they actually are73. This is the cause of much 
defensive medicine. This is particularly true with respect to end-of-life care74  
In order to investigate the impact of legal uncertainty on LST-related decisions, 
the conceptual framework of Kelly et al. could not be used in this study. Therefore, 
a new conceptual framework was proposed in this study based on the literature 
about defensive medicine and legal defensiveness.  
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2. Legal defensiveness-induced LST 
 
Although refusal must be made ahead-of-time, many decisions about 
life-sustaining treatment concern patients who have lost their decision-making 
capacity21. These patients cannot personally and legally refuse treatment at the 
time its use becomes necessary. In this circumstance, a surrogate makes an 
LST-related decision. If the surrogate is a family member of a dying patient, an 
LST-favoring decision would be made under the ethical burden to actively hasten 
the death of a dying patient. In conjunction with patient side source, under the 
nonexistence or unavailability of an advance directive, physicians generally prefer 
to provide LST.  
In his brilliant study, legal scholar Pope suggested two factors produce this 
preference21. First, when the patient has not declared the treatment to be unwanted, 
it is presumed that it is wanted75. End-of-life medicine is like a train that will 
proceed to the final stop, unless the patient has a valid ticket to disembark at an 
earlier station. Second, as a result of inertia instead of a deliberate choice, most 
patients have failed to rebut that presumption. In addition to the factors suggested 
by Pope, the situations when CPR, MV, and ICU care are needed are typically 
urgent emergency states. There is no time to get informed consent from the patient. 
Physicians have no option but to provide LST to the dying patient. 
Importantly, with respect to administering LST without consent, physicians’ 
perception is that the legal risks are lower than they actually are21. The general 
view from the medical front is that you cannot be sued for doing too much, you 
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can only be sued for doing too little45,76-78. Indeed, a 2012 survey found that a 
majority of physicians agree that there is less liability risk for "maintaining 
someone alive against their will than mistakenly allowing them to die"5. Attorneys 
often advise health care institutions and physicians to "play it safe" when in doubt 
and just administer treatment79. This advice seems consistent with the literature. 
Legal commentators have generally agreed that "there are few, if any, effective 
incentives for physicians and other healthcare providers to be scrupulous in their 
adherence to advance directives"80. Neither judges nor lawmakers have yet 
formulated coherent or effective remedies for physicians' failures to comply with 
the instructions patients have provided80,81.  
Yet another situation in which clinicians often provide unwanted life-sustaining 
treatment is at the demand of the patient's own surrogate. Even if a patient has an 
advance directive refusing treatment, advance directives are rarely self-executing. 
Clinicians usually turn to the patient's surrogate for direction. But, 
notwithstanding the patient's clear intent in the advance directive to refuse 
treatment, the surrogate often wants to continue treatment21. Physician’s fear of 
the family as a potential plaintiff means that the family member’s demand for LST 
virtually always controls the situation regardless of medical futileness45,82. “Dead 
patient don’t sue, but live families do” is veritable mantra among physicians45. 
In such conflict situations, clinicians are overwhelmingly prepared to override 
the patient's advance directive at the surrogate's request. A choice between the 
liability risk posed by an emotionally distraught family and that posed by a 
vegetative patient who will never regain consciousness is not much of a choice. In 
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addition, liability is not the clinician's only concern. Even prevailing parties pay 
transaction costs. An angry surrogate's action, "even if frivolous will cost the 
provider in legal fees, stress, and perhaps even professional reputation." When the 
patient's potential surrogates cannot agree on a decision or plan, the clinician may 
be hesitant to stop life-sustaining treatment. Clinicians err on the side of 
continuing treatment when surrogates provide no clear direction, preferring to 
wait until consensus develops21 
If a physician have a vitalistic philosophy of medicine, things get worse. There 
remains a significant amount of physician paternalism. Many physicians are not 
ready to give up. In general, many physicians still consider it their responsibility 
to make treatment decisions that they believe are in the patient's best interest and 
that patient preferences should be ignored if they are inconsistent with the 
physician's view of the patient's best interests83. Even when physicians know a 
patient's preference, they may disregard it as not in the patient's best interests84,85. 
Clinicians may object to complying with patient wishes not only on 
professional or paternalistic grounds, but also on personal grounds21. For example, 
"a healthcare provider may have a powerful personal moral bias that all life is 
worth saving and that everything possible should be done for every patient." 
Another reason that clinicians administer unwanted life-sustaining treatment is 
that overtreatment is well-reimbursed86,87. Clinicians are often paid more for 
doing more88. The current fee-for-service reimbursement model incentivizes 
clinicians to provide more treatment and to deploy more technology, even more 
than the patient desires89. 
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In East Asia, cultural influence strongly affects physicians’ LST-related 
decision70,90. Although physicians in East Asian countries face ethical problems 
similar to those of their western counterparts, they are different from those of 
western countries in cultural traditions, customs, religious beliefs, and ethnic 
backgrounds. Although advance directives are essential for communicating 
intentions before death, it is almost impossible for the majority of Korean patients 
to provide such an advance directive25. In East Asian countries where family-
oriented values are shared (i.e., Confucius values), most decision making, even 
medical decisions, are made by families. The truth with regard to the seriousness 
of a patient’s illness is generally kept hidden by the family members from the 
patient to prevent any negative emotional influence3,91. 
Confucianism does not advocate forgoing of life sustaining treatment for 
patients92. In addition, physicians may encounter severe social criticism if a 
terminally ill older patient is allowed to die or denied a life-saving intervention70. 
Similarly, the patient’s family members might be blamed by other members of 
society for violating the principle of filial piety or criticized for being 
anti-humanitarians3,70. In East Asian countries, the social idea and norm of the 
Confucian value of filial piety is commonly shared, and there is an expectation 
that children should work to save their parents with all their strength regardless of 
the costs70. The lasting influence of Confucianism is apparent in these 
family-centered Asian societies as reflected by the importance that is placed on 
ancestor-worship, patriarchy, and filial piety93. In the US setting, minority 
populations such as Asian Americans are less likely to access hospice care 
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compared with white Americans87,94,95.  
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3. Legal defensiveness model used in this study 
 
Prior studies regarding defensive medicine in general and legal defensiveness 
specific to forgoing LST altogether contributed to developing the conceptual 
framework for the legal defensiveness model in this study. In particular, the legal 
defensiveness model integrates and reconstructs determinants proposed by Kelley 
et al.8 into the model focusing on physicians’ legal defensiveness toward 
LST-related decisions. The theoretical background from legal defensiveness 
proposed by McCrary and Swanson67 played a pivotal role in incorporating 
perceived legal uncertainty or ambiguity stemming from misunderstanding laws. 
Pioneering research of Pope21 about legal aspects of LST and physicians’ inertia 
toward administering LST provided significant implications for psychological and 
legal burdens or fears of physicians. 
Nevertheless, literature describes mechanisms from which legal defensiveness 
stemmed and how legal defensiveness could influence LST-related decisions 
listed associated factors in parallel21,45,67,73,96. Therefore, in order to advance the 
progress of the study objectives, the following conceptual framework for a legal 
defensiveness model provides for a possible mechanism to explain the association 
between physicians’ legal defensiveness and forgoing LST.  
If there are laws or judicial precedents governing LST, they set the range of 
allowed and prohibited behaviors toward physicians. On the other hand, the legal 
system could clarify legal disadvantages that will be incurred if those behaviors 
are recognized as illegal. Above the range and disadvantages constructs an 
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objective legal stability, which is the objective in terms of its irrelevance to 
perceptions of individual physicians. On the contrary, if there are not laws or 
judicial precedents governing LST, then considerable objective legal ambiguity or 
instability occur and debates on legality of forgoing LST can arise among the 
judicial world. 
Regardless of objective legal ambiguity, individual physicians might perceive 
objective legal ambiguity differently, and even misunderstand the law as in the 
Boramae case. In other words, physicians’ perception of legality is subjective and 
could conflict with objective legality in the present legal system. Individual 
perceptions of subjective legal instability or ambiguity finally constructs legal 
defensiveness toward forgoing LST.  
In this study, physicians’ legal defensiveness was defined as the attitude formed 
accumulatively by influences and interactions of various factors such as 
physicians’ knowledge of law, level of fear for liability, prior experience of legal 
disputes, intrinsic characteristics such as age and sex, practice patterns of 
doctor-patient relationships, and individual values about life and religion. The 
legal defensiveness ensconced deeply in physicians’ minds is expressed by the 
preference for LST in individual cases. The preference for LST depends on the 
factors such as presence of advance directives and patient’s age within that 
individual case. Experiences during formation of preferences for individual cases 
can affect legal defensiveness. Behaviors incorporated into the legal system 
including informed consent, advance directives, and POST can affect the doctor-
patient relationship, and changes in the doctor-patient relationship can influence 
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general legal defensiveness and specific preference for LST in an individual case. 
Again, legal defensiveness and preference influence the doctor-patient 
relationship and determine the level of participation of the patient side in LST-
related decision making. 
Although many factors could affect a physician’s preference for LST in an 
individual case, legal defensiveness toward LST plays a major role. Legal 
defensiveness-induced preferences determine the decisions about LST in an 
individual case. The level of force differs according to the medical urgency and 
legal risk. Legally high-risk LST such as CPR, MV, and ICU care are 
administered primarily by physician-driven decisions and are medically urgent in 
terms of high risk of immediate death. In contrast, legally low-risk LST such as 
ED visits and acute hospital admission are utilized by patient-driven decisions as 
well as physicians’ decisions in terms of low risk about the immediate decision. 
The higher the legal risk, the less likely it is that decision to forego LST be made. 
The conceptual framework for a legal defensiveness model is presented as a flow 
chart focusing on legal aspects (Figure 1). 
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Figure 1 Conceptual framework of legal defensiveness model in this study 
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Ⅳ. Materials and Methods 
 
1. Study subjects and data source 
 
The study population was decedents aged 70–89 with cancer, circulatory, or 
respiratory diseases between 2003 and 2013 in South Korea. Inference about the 
study population was performed through analyses of a 10% simple random 
sample from the study population. The random sample of the study population 
was obtained from the National Health Insurance Service–Elderly Cohort 
(NHIS-NSEC)97. The NHIS-NSEC was constructed for the purpose of providing 
public health researchers and policy makers with representative, useful 
information regarding citizens’ utilization of health insurance and health 
examinations97. Data and a manual can be accessed through the NHIS’ National 
Health Insurance Data Sharing Service website 
[https://nhiss.nhis.or.kr/bd/ab/bdaba008cv.do]. 
The target population of NHIS-NSEC was people older than 60 years in 2002 in 
South Korea. From the target population consisting of about 0.5 million enrollees 
in the National Health Insurance (NHI) and medical aid beneficiaries, 588,147 
participants of the HNIS-NSEC were randomly selected through 10% simple 
random sampling. Therefore, the NHIS-NSEC can represent the South Korean 
population older than 60 years in 2002. The participants were followed for 12 
years until 2013 unless participants’ eligibility was disqualified due to death or 
emigration. Since initial enrollment in 2002, additional enrollment of a new 
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subject was not permitted in the NHIS-NSEC. Therefore, the study population’s 
representativeness is not guaranteed during the follow-up period, because during 
the follow-up period, participants were getting older and dying and the remaining 
participants could not represent the South Korean population older than 60 years. 
To maintain the representativeness of the data and control for a changing age 
distribution, study participants were limited to decedents aged 70–79 at death. The 
information in the data set included all inpatient and outpatient medical claims 
data, including personal information, prescription drugs, diagnostic test and 
treatment procedure codes, and primary and secondary diagnosis codes. In 
addition, each patient’s unique de-identified number was linked to mortality 
information from the Korean National Statistical Office. To protect participants’ 
privacy, the Resident Registration Number that was initially used to construct the 
cohort was replaced with a newly-assigned eight-digit personal identification 
number. 
Under the retrospective framework, decedents were identified between 2003 
and 2013 by a death certificate with the unique identification number and the 
cause of death. Initially 108,548 decedents with cancer, circulatory, or respiratory 
diseases were selected (Figure 2). To preserve representativeness of data, 23,664 
decedents aged less than 70 or more than 89 were excluded. Until 2008, claims 
information about medical aid beneficiaries was not reliable, and therefore 12,391 
decedents who were beneficiaries of the medical aid program were excluded. 
Under the assumption that decedents without any health care utilization might not 
have exact death certificates, 1,972 decedents with that condition were excluded. 
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Finally, study decedents consisted of a total of 70,521 decedents who were 70–89 
years old at the time of death.
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Figure 2 Description of the process to construct the KNHIS-NSEC and the 
selection of dying patients from the KNHIS-NSEC 
 
39 
 
2. Study Design 
 
(1) Retrospective observation study 
 
A retrospective observation study of decedents with cancer, circulatory, and 
respiratory diseases was conducted in this study. Time series were constructed by 
time unit of a quarter from 2003 to 2013. During 44 quarters, decedents were 
classified to corresponding quarters according to their dates of deaths. Outcomes 
were identified retrospectively since the date of death to the last 30 and 180 days 
of life. The time series were interrupted at the specific break points that divided 
study periods into segments according to the legal defensiveness toward 
LST-related decisions. Within the time series, trends and its changes of outcomes 
were measured and compared between these segments.  
In this study, the exact time of entering the dying end-of-life phase could not be 
identified easily due to the nature of administrative claims data. The attempt to 
identify dying end-of-life phase patients and conduct a prospective study was not 
feasible under the limitation of administrative claims data. By conducting a 
retrospective study, the selection of cases is not dependent on inaccurate 
investigator prognostication of survival98. Therefore, a retrospective observational 
study was selected as the optimal study design for this study. 
 
(2) Division of period on the basis of physician’s legal defensiveness 
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The study period 2003–2013 was divided into distinct periods according to the 
physicians’ legal defensiveness based on legal circumstances and the social 
atmosphere.  
First, through qualitative and empirical analysis, two attorneys at law with 
medical doctor qualifications listed and reviewed meaningful events related to 
LST in chronological order (Table 1). After a discussion, the Boramae hospital 
case during 1998–2004 and the Grandma Kim Case during 2008–2009 were 
chosen as the landmark events that influenced physicians’ legal defensiveness 
toward LST-related decisions. Whereas the break point in the first quarter of 2010 
was a relatively clear point where the time series was interrupted by a major event 
such as the Supreme Court judgment for Grandma Kim’s case and death of 
Gramm Kim, the break point in the first quarter of 2007 was a relatively vague 
point where publically sensational events were absent. However, in addition to the 
two monumental court decisions, some important LST-related news items were 
reported through mass media and medical media in the second quarter of 2007, 
and so they could not be neglected. The first case reported that physicians who 
had removed MV from a terminal cirrhosis patient were approved to be free from 
suspicion by the prosecution99,100. The KBS’s Tracking 60 Minutes, the 
high-profile investigative TV program on public service broadcasting, covered a 
murder case in which a father removed MV from his son in vegetative state101. 
Although these not widely known events might not influence the general medical 
community, specialists engaged in LST who are very sensitive to the LST-related 
news could be affected considerably.  
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Summarizing the events listed above, two possible divisions of time series were 
suggested. One was three distinct periods of increasing (2003–2006), conflicting 
(2007–2009), and relieving (2010–2013), the other was increasing (2003–2009) 
and relieving (2010–2013).  
Second, the basis for supporting the above qualitative division was provided by 
the quantitative analysis of attention to LST among the general public and 
physicians. In order to measure the degree of attention of the South Korean people, 
a Google trend analytics search was carried out using Korean terms meaning 
Boramae hospital case, life-sustaining treatment, death with dignity, and related 
terms in South Korea, which tracked the popularity of peak searching for this term 
from 2004 (Appendix 1). The Google trend analytics was used in a previous study 
to find a time point when the general public was interested in specific subject 
broadcasted through mass media102. The analysis found increased public attention 
to LST-related terms during the conflicting period (2007–2009) of legal 
defensiveness followed by decreasing attention during end of the increasing 
period.  
To measure the degree of attention of physicians, the number of news items 
mentioning the Boramae hospital case, life-sustaining treatment, death with 
dignity, and related terms from the Newspapers of the Korea Medical Association 
were measured (Appendix 2). Similar to the general public, the analysis found that 
physician’s attention to LST-related terms had increased during the conflicting 
period (2007–2009) of legal instability followed by decreasing attention during 
the end of the increasing period. Based on the analyses of degree of attention paid 
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to LST, the division of time series into three periods seemed to be more 
reasonable than division into two periods. 
Third, in order to assist in selecting break points of the time series, descriptive 
statistics of outcome measures over time were used as supplementary and 
empirical information (Figure 3 and 4). Although there were variations among 
outcome measures, the first quarter of 2007 and 2010 were selected as break 
points to divide the time series into three periods of legal defensiveness in this 
study.  
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Table 1 Major events concerning life-sustaining treatment 
 
 
  
Time series Major events 
1998. May. The first trial judgment of the Boramae Hospital case 
2002. Feb. The appellate court’s judgment of the Boramae Hospital case 
2004. Jun The Supreme Court’s judgment of the Boramae Hospital case 
2005. Mar. Media coverage of Terry Schiavo case 
2007. Jun. Media coverage of Jack Kevorkian’s release and Korean broadcasting’s 
interview with him103   
2007. Jul. Media coverage that physicians who had removed MV from terminal 
cirrhosis patient approved free from suspicion by the prosecution  
2007. Aug. Media coverage of the murder case in which a father removed MV 
from his son in vegetative state 
2008. May. The first media coverage of the Grandma Kim case 
2008. Nov. The first trial judgment of the Grandma Kim case 
2009. Feb. The appellate court’s judgment of the Grandma Kim case 
2009. May. The Supreme Court’s en banc judgment of the Grandma Kim case 
2009. Dec. The pilot project for hospice palliative care 
2010. Jan. Death of the Grandma Kim after 6 months from removal of MV104 
2016. Feb. Enactment of the Hospice-Palliative Care and Decision on Life-
sustaining Treatment Care of Dying Patients Act (enacted by Act No. 
14013, Feb.34, 2016) 
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1) The first period: increasing legal defensiveness (2003–2006) 
 
The first period was when physicians became aware of the legal burden of aid 
and abetment of murder around the Boramae Hospital case that progressed 1998–
20044. In this period many physicians recognized that forgoing LST was illegal or 
at least legally very risky2,3,30,40,42. Although there was no specific law governing 
LST, physicians’ legal defensiveness toward LST-related decisions was so high 
that physicians were reluctant not only to withdraw or withhold LST but also to 
agree with hopeless discharge from hospitals31,40,41. The perceived legal 
uncertainty or ambiguity was excessively high compared with the objective legal 
uncertainty or ambiguity. Under the high burden of legal risk, physicians had a 
diminished need to ask the patient side about the willingness to receive LST. It 
was a safe decision to delay the time of death by providing LST until the patient 
entered the natural dying process3,41. 
Characteristics in this period were: 1) it was difficult to expect shared decision 
making in the patient-doctor relationship with regard to discontinuation of LST; 
and 2) the physicians played a leading role (paternalism) in LST-related decision 
making, and actively initiated LST such as CPR and MV if a patient experienced 
life-threatening conditions such as cardiopulmonary arrest.  
 
2) The second period: conflicting legal defensiveness (2007–2009) 
 
The second period is when public needs for forgoing LST had increased and 
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cases favorable to forgoing LST were covered by mass media. In the process of 
the long-running Boramae Hospital case, there was a great deal of controversy 
and debate among the general public as well as in the academic world. In the 
meantime, changes and conflicts of legal defensiveness arose among physicians. 
In the process of the Grandma Kim case, a favorable atmosphere toward foregoing 
LST had developed among the general public as well as in the academic world. In 
the meantime, social consensus on the need to introduce hospice care had been 
developing since the Boramae Hospital case.  
This period was characterized by physicians becoming more willing to initiate 
discussions about LST with the patient side (shared decision making), so the 
chance to make decisions in advance of an emergency situation requiring CPR or 
MV increased. 
 
3) The third period: Relieving legal instability (2010–2013) 
 
In the third period, under the influence of the Grandma Kim case, physicians’ 
legal defensiveness was considerably relieved. In the circumstance that a specific 
law governing LST had not been enacted, the judicial precedent of the Grandma 
Kim case guaranteed the legality of forgoing LST to physicians. Under the 
intrinsic limitation of the judiciary in relation to the legislature, because detailed 
substantive and especially procedural requirements for forgoing LST was 
insufficient for physicians to be immune from litigation, considerable legal 
defensiveness has remained. In the meanwhile, a movement for enacting a specific 
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law governing LST progressed during this period and finally the LST Act was 
enacted in February 3, 2016. 
This period was characterized by physicians perceiving that forgoing LST is not 
illegal and hence were more actively able to decide to not administer LST for a 
dying patient than in the prior two periods. However, legal uncertainty or 
ambiguity for procedural requirements for legal immunity did remain among 
physicians. 
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(3) Natural experimental characteristics 
 
The three periods of legal defensiveness simulates an experimental design 
occurring in real world settings. Because legal defensiveness sharply increased 
during the first period and decreased during the second period, it looks like two 
policy interventions were implemented nationally (Table 2)105.  
 
Table 2 Characteristics as a natural experiment 
 
Increasing  
legal defensiveness  
Conflicting  
legal defensiveness 
Relieving  
legal defensiveness 
Duration 1998-2006 2007-2009 2010 and later 
Influencing 
event Boramae hospital case 
Cirrhosis case,  
Boramae hospital case, and 
Grandma Kim’s case 
Grandma Kim’s 
case 
Perceived legal 
uncertainty 
Illegal  
for forgoing LST 
Change from Illegal to legal  
for forgoing LST 
Legal  
for forgoing LST 
Legal 
defensiveness High 
Change from high to 
medium Medium 
Force of 
initiating LST High 
Change from high to 
medium Medium 
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3. Outcomes 
 
(1) Legally high-risk LSTs and control outcomes 
 
There is no previous study suggesting LST-related outcomes according to the 
level of legal risk. However, Earle et al. proposed indicators of the quality of 
end-of-life cancer care from administrative data after reviewing literature, focus 
group interviews, and Delphi methods106,107. These indicators have been used in 
many articles investigating quality of care at end-of-life9,108,109. Focusing on 
treatment intensity, Barnato et al. proposed indicators including CPR and MV to 
measure hospital end-of-life treatment intensity110. Another review article 
summarized outcome measures in end-of-life cancer care but the outcomes were 
classified as aggressive or palliative care87. Because legal aspects were not 
incorporated into the above quality or intensity indicators of end-of-life care, new 
classifications according to the level of legal risk were needed in this study. 
Two attorney-at-laws with medical doctor qualifications including the author 
selected LST-related outcomes according to the level of legal risk under the legal 
defensiveness model. Legally high-risk outcomes included CPR and MV. In most 
legal cases for LST, removing MV has taken the center of controversy. If CPR and 
MV are not provided during an urgent crisis of life, patients die quickly. If there 
were not advanced directives or POLST available, legally high-risk outcomes tend 
to occur immediately. Typically done under an urgent emergency state, the 
decision whether to do or not to do is driven mainly by physicians. Hospital 
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admission and per capita hospital days among entire study decedents were 
selected as control outcomes. Decisions as to whether to do or not to do for these 
outcomes are made mainly by the patient side as well as physicians and these 
control outcomes generally are not closely related to immediate death risk.  
 
(2) Outcome measurement  
 
Taking into account the strength and limitations of the NHIS-NSEC, 
LST-related outcomes were measured by appropriate methods. In South Korea, 
most of the reimbursement by the NHIS was provided mainly based on 
fee-for-service and reimbursement to physicians and hospitals are not separated. 
Thus, for reimbursement, medical institutions should claim all individual services 
to the NHIS. These claims are first reviewed by the Health Insurance Review and 
Assessment Service, and if there are false claims then economic and 
administrative sanctions could be imposed on that medical institution. Although a 
small portion of reimbursement for inpatient care is provided by diagnosis-related 
groups, those diseases are not related to LST. Healthcare utilization of dental and 
traditional Korean (or Chinese) medicine was not included in this study.  
Outcomes were measured individually with corresponding information 
including the date and unique patient and hospital identification numbers. In 
South Korea, hospitals are classified into four categories according to the Medical 
Law. Classification into clinic, acute care, and long-term care hospitals were 
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based on the medical care institution database containing information regarding 
the type of institution, establishment, location, number of beds, facilities, and 
physicians. Because tertiary hospitals were not identified directly from the 
NHIS-EC, admission fees for tertiary hospitals were used for identifying tertiary 
hospitals111.  
Providing CPR and MV according to institution types were identified by the 
presence of corresponding treatment procedure codes. MV included artificial 
ventilation through trans-tracheal and intra-tracheal catheter insertion. If MV was 
provided during anesthesia for surgery then it was excluded. Providing CPR and 
MV were considered to be present if the claims bill had a starting date during the 
decedent’s last 30 days of life.  
An admission to hospitals according to institution types were identified by 
claims bills that provides whether that claim was based on outpatient or inpatient 
care. Because the date of discharge was calculated by adding length-of-stay (LOS) 
to the date of admission, depending on the exact time of admission and discharge 
date, the calculated date of discharge could be one day later or earlier than the 
actual date of discharge. If the date of admission or discharge was within the last 
30 days of life then the patient was considered to be admitted to hospital. Per 
capital hospital days according to institution types were calculated based on 
admission and discharge dates. Hospital days belonging to each admission were 
distributed to hospital days corresponding to the last 30 days of life. 
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4. Covariates 
 
Sex and age in years at death were included as demographic variables9,12,112. 
According to type of health insurance, decedents were classified into employees 
or self-employed individuals and their dependents. Residential area was divided 
into 1) a metropolitan area that included Seoul and six metropolitan cities or 2) a 
nonmetropolitan area otherwise. Household income level was identified from the 
10 levels of the NHI premium. The premium level was categorized into low, 
meddle, and high tertiles among the study decedents. The decedent’s level of 
comorbidities was assessed by diagnostic codes during the 720 days before death 
using the Quan’s International Statistical Classification of Disease and Related 
Health Problems, 10th Revision (ICD-10) coding algorithm of the Charlson 
Comorbidity Score (CCS)113,114. The presence of disease constituting disease 
categories of the CCS was defined by at least two outpatient visits or one 
admission upon the primary or the first secondary diagnosis. Diseases 
corresponding to causes of death were not excluded during calculation of the CCS. 
Presence of registered disability was identified by the insurance eligibility 
database of the NHI. In order to control for seasonality and therefore 
autocorrelation, four quarters of a year were included as a covariate115. Causes of 
death were identified through death certificates provided by the National 
Statistical Office in Korea97. According to the ICD-10, causes of death were 
classified into cancer (C00-C97), circulatory diseases (I00-I99), or respiratory 
diseases (J00-J99).  
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5. Subgroup and sensitivity analyses 
 
The study decedents consisted of patients with cancer, circulatory, or 
respiratory diseases. These three causes of death have different characteristics of 
clinical progress. Hence, three separate analyses corresponding to the causes of 
death were performed and the results were compared under the assumption that if 
the preexisting level of LST is high then the magnitude of decrease would be high.  
In the main analysis, the effect of increased medical resources such as hospital 
beds could have increased LSTs8. Such mixture of effects makes it hard to 
interpret the main results. Therefore, a sensitivity analysis was conducted with the 
decedents who were admitted to hospitals during their last 180 days of life. In 
addition to the covariates included in the main analysis, the type of medical 
institution where the decedents were last admitted was added to the 
multivariable-adjusted regression model. 
Regarding the division of three periods according to the level of physicians’ 
legal defensiveness, a sensitivity analysis using two periods was done. The first 
period started in the first quarter of 2003 and ended in the second quarter of 2009 
when the Supreme Court Decision of the Grandma Kim case was announced. 
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6. Statistical analysis 
 
In order to analyze time trend and its changes of LST-related outcomes, 
interrupted time series (ITS) with segmented regression was conducted. A time 
series is defined as a continuous sequence of observations on a population, taken 
repeatedly over time115. In an ITS with segmented regression, an underlying or 
baseline trend is constructed by using a time series of an outcome variable. This 
baseline trend is interrupted by an intervention or event at the break point115. 
The hypothetical scenario called the counterfactual is the expected trend in the 
absence of the intervention. Had it not been for the intervention, the underlying 
trend would continue. Comparison of the counterfactual and observed outcomes 
in post-intervention could provide a way for investigating the effect of the 
intervention. An ITS study is generally robust to typical confounding variables 
which remain fairly constant, such as population age distribution or 
socioeconomic status, as these only change relatively slowly over time and are 
normally taken into account when modeling the underlying long-term trend115. 
In a simple form, ITS is modeled using a linear regression model that includes 
three time-related variables, whose regression coefficients estimate the 
pre-intervention slope, the change in level at the time of intervention, and the 
change in slope from pre-intervention to post-intervention105. The pre-intervention 
slope represents the baseline trend for the outcome prior to the intervention105. 
The change in slope quantifies the difference between the pre-intervention and 
post-intervention slopes. The level change represents the absolute change of 
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outcome level at the time of the intervention, which measures the immediate 
effect of intervention between the time point immediately before and immediately 
after the break point105. 
In this study, the time series of LST-related outcomes of decedents was 
interrupted by two break points. The first break point was the first quarter of 2007 
where the periods of increasing and conflicting legal defensiveness were divided. 
The second break point was the first quarter of 2010 where the periods of 
conflicting and relieving legal defensiveness were divided. 
A generalized linear model (GLM) with a Poisson distribution and logarithmic 
link function was used in segmented regression. If a Poisson regression is applied 
to binomial data, the error for the estimated relative risk will be 
overestimated116,117. To avoid overestimating the standard errors of the parameter 
estimates, a generalized estimating equation using a robust standard error was 
employed116,118,119. Because this model used a logarithmic link function, model 
coefficients needed to be transformed into exponentials to present the trend and 
change of outcomes in the original scale. Additive interpretation of the model 
coefficients for Log[E(𝑌𝑖)] were transformed to multiplicative interpretations for 
the original scale, E(𝑌𝑖) = 𝜇𝑖.  
First, coefficients were estimated through the GLM described above: 
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log(𝜇𝑖) =  𝛽0 + 𝛽1�𝑇𝑇𝑇𝑒𝑏𝑒𝑓𝑜𝑟𝑒� + 𝛽2�𝑇𝑇𝑇𝑒𝑑𝑢𝑟𝑖𝑛𝑔� + 𝛽3�𝑇𝑇𝑇𝑒𝑎𝑓𝑡𝑒𝑟�+ 𝛽4�𝐼𝐼𝐼𝑒𝐼𝐼𝑒𝐼𝐼𝑇𝐼𝐼1𝑑𝑢𝑟𝑖𝑛𝑔� + 𝛽5�𝐼𝐼𝐼𝑒𝐼𝐼𝑒𝐼𝐼𝑇𝐼𝐼2𝑎𝑓𝑡𝑒𝑟𝑟�+ �𝛾𝑘𝑋𝑘𝑖 
 
𝑇𝑇𝑇𝑒𝑏𝑒𝑓𝑜𝑟𝑒 : a continuous time variable range from 0 to 43 starting in the first 
quarter of 2003 
𝑇𝑇𝑇𝑒𝑑𝑢𝑟𝑖𝑛𝑔 : a continuous time variable range from 0 to 27 during the second 
and third period, starting in the first quarter of 2007 
𝑇𝑇𝑇𝑒𝑎𝑓𝑡𝑒𝑟 : a continuous time variable range from 0 to 15 during the third 
period, starting in the first quarter of 2010 
𝐼𝐼𝐼𝑒𝐼𝐼𝑒𝐼𝐼𝑇𝐼𝐼1𝑑𝑢𝑟𝑖𝑛𝑔 : an indicator variable set to 1 during the second and 
third period  
𝐼𝐼𝐼𝑒𝐼𝐼𝑒𝐼𝐼𝑇𝐼𝐼2𝑎𝑓𝑡𝑒𝑟 : an indicator variable set to 1 during the third period  
𝑋𝑘𝑖: a covariate vector of the 𝑇𝐼ℎ individual  
 
In the logarithmic scale of 𝜇𝑖, 𝛽1 is the time fixed effects representing the 
underlying baseline trend during the entire period, 𝛽2 represents the slope change 
of the second period compared to the first period, and 𝛽3 represents the slope 
change of the third period compared to the second period. 𝛽4 represents the level 
change at the time of the first break point in the first quarter of 2007 and 𝛽5 
represents the level change at the time of the second break point in the first quarter 
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of 2010. 𝛾𝑘 is the fixed covariate effects. 
Second, the coefficients of GLM were transformed to exponentials for 
interpretation of the original scale of outcomes. 
 
𝜇𝑖 = 𝑒  𝛽0+𝛽1�𝑇𝑖𝑚𝑒𝑏𝑒𝑓𝑜𝑟𝑒�+𝛽2�𝑇𝑖𝑚𝑒𝑑𝑢𝑟𝑖𝑛𝑔�+𝛽3�𝑇𝑖𝑚𝑒𝑎𝑓𝑡𝑒𝑟�+𝛽4�𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛1𝑑𝑢𝑟𝑖𝑛𝑔�+𝛽5�𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛2𝑎𝑓𝑡𝑒𝑟𝑟�+∑𝛽𝑘𝑋𝑘𝑖  
 
Interpretation of 𝛽1 is that the expected value of outcome Y increases 𝑒𝛽1 
times per quarter during the first period. In other words, the average increasing 
rate during the first period was 𝑒𝛽1 per quarter or (𝑒𝛽1 − 1) × 100% per quarter. 
During the second period, the quarterly increasing rate is 𝑒𝛽1+𝛽2, and this rate is 
𝑒𝛽2  times higher than that of the first period. During the third period, the 
quarterly increasing rate is 𝑒𝛽1+𝛽2+𝛽3, and this rate is 𝑒𝛽1+𝛽2  times and 𝑒𝛽3 
times higher than that of the first period and second period, respectively. 
Interpretation of 𝛽4 and 𝛽5 is that the expected value of outcome Y increased 
immediately 𝑒𝛽4 and 𝑒𝛽5 times at the time of the first and second break points. 
Third, quarterly increasing rates were converted to annual increasing rates 
(AIR). 
 AIRbefore = e4β1 AIRduring = e4β1+4β2 AIRafter = e4β1+4β2+4β3 
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Rate ratios between the three periods were calculated through dividing the AIR 
of second and third period by the AIR of the first period.  
All statistical analyses were conducted using SAS (Version 9.4, SAS Institute 
Inc., Cary, NC). A P value < 0.05 was considered statistically significant. 
 
7. Ethics statements 
 
This study was approved by the Institutional Review Board of the Graduate 
School of Public Health, Yonsei University. [IRB number 2-1040939-AB-N-01-
2016-412-01] 
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Ⅴ. Results 
 
1. Characteristics of study decedents 
 
Among 71,702 decedents during 2003–2013, 30,173 cancer patients, 30,336 
circulatory disease patients, and 10,012 respiratory disease patients died (Table 3). 
Male decedents made up 53.7% and the mean age was 78.9. Distributions of age 
and sex between the three periods were statistically different but the differences 
were not large. The Charlson comorbidity score increased from 3.6 to 5.1 during 
study period. Decedents with cancer decreased from 40.3% to 44.3% and 
decedents with circulatory disease decreased from 46.3% to 40.4% during the 
study period. Seasonality across quarters of a year was not prominent. 
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Table 3 General characteristics of elderly decedents according to the period of physicians' legal defensiveness toward life-
sustaining treatment (continued) 
    Physicians' legal defensiveness  
Characteristics 
Entire period  Increasing period  Conflicting period  Relieving period  
(2003–2013)  (2003–2006)  (2007–2009)  (2010–2013) P value 
Decedents 70,521   22,032   19,135   29,354   
Sex            <0.001
a 
Male 37,982 (53.9)  11,595 (52.6)  10,375 (54.2)  16,012 (54.5)  
Female 32,539 (46.1)  10,437 (47.4)  8,760 (45.8)  13,342 (45.5)  
Age (years)             
70–74 18,289 (25.9)  6,209 (28.2)  5,220 (27.3)  6,860 (23.4) <0.001
a 
75–79 20,516 (29.1)  6,596 (29.9)  5,395 (28.2)  8,525 (29.0)  
80–84 18,765 (26.6)  5,834 (26.5)  4,947 (25.9)  7,984 (27.2)  
85–89 12,951 (18.4)  3,393 (15.4)  3,573 (18.7)  5,985 (20.4)  
Mean (SD) 78.8 (5.4)  78.4 (5.3)  78.7 (5.4)  79.2 (5.4) <0.001
b 
Median (IQR) 79.0 (9.0)  78.0 (9.0)  79.0 (9.0)  79.0 (9.0) <0.001
c 
Type of national health insurance            <0.001
a 
Self-employed 10,992 (15.6)  4,241 (19.2)  2,506 (13.1)  4,245 (14.5)  
Dependent of self-employed 14,043 (19.9)  4,746 (21.5)  4,111 (21.5)  5,186 (17.7)  
Employee 491 (0.7)  160 (0.7)  128 (0.7)  203 (0.7)  
Dependent of employee 44,995 (63.8)  12,885 (58.5)  12,390 (64.8)  19,720 (67.2)  
Residential area            0.653
a 
Metropolitan 26,974 (38.2)  8,443 (38.3)  7,359 (38.5)  11,172 (38.1)  
Non-metropolitan 43,547 (61.8)  13,589 (61.7)  11,776 (61.5)  18,182 (61.9)  
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    Physicians' legal defensiveness  
Characteristics 
Entire period  Increasing period  Conflicting period  Relieving period  
(2003–2013)  (2003–2006)  (2007–2009)  (2010–2013) P value 
Household income level            <0.001
a 
Low 19,652 (27.9)  6,421 (29.1)  5,335 (27.9)  7,896 (26.9)  
Middle 23,430 (33.2)  7,304 (33.2)  6,337 (33.1)  9,789 (33.3)  
High 27,439 (38.9)  8,307 (37.7)  7,463 (39.0)  11,669 (39.8)  
Charlson Comorbidity Score            <0.001
a 
0–1 13,276 (18.8)  6,873 (31.2)  2,942 (15.4)  3,461 (11.8)  
2–5 21,415 (30.4)  7,268 (33.0)  5,894 (30.8)  8,253 (28.1)  
6–7 19,639 (27.8)  3,790 (17.2)  5,595 (29.2)  10,254 (34.9)  
≥8 16,191 (23.0)  4,101 (18.6)  4,704 (24.6)  7,386 (25.2)  
Mean (SD) 4.5 (3.4)  3.6 (3.2)  4.8 (3.4)  5.1 (3.4) <0.001
b 
Median (IQR) 4.0 (5.0)  3.0 (4.0)  4.0 (5.0)  4.0 (5.0) <0.001
c 
Disability            <0.001
a 
No 69,221 (98.2)  21,762 (98.8)  18,710 (97.8)  28,749 (97.9)  
Yes 1,300 (1.8)  270 (1.2)  425 (2.2)  605 (2.1)  
Quarter of Year at death            0.003
a 
First 18,428 (26.1)  5,836 (26.5)  4,923 (25.7)  7,669 (26.1)  
Second 17,289 (24.5)  5,516 (25.0)  4,728 (24.7)  7,045 (24.0)  
Third 16,448 (23.3)  5,157 (23.4)  4,425 (23.1)  6,866 (23.4)  
Fourth 18,356 (26.0)  5,523 (25.1)  5,059 (26.4)  7,774 (26.5)  
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    Physicians' legal defensiveness  
Characteristics 
Entire period  Increasing period  Conflicting period  Relieving period  
(2003–2013)  (2003–2006)  (2007–2009)  (2010–2013) P value 
Cause of death d            <0.001
a 
Cancer 30,173 (42.8)  8,879 (40.3)  8,295 (43.3)  12,999 (44.3)  
Bronchus and lung 7,643 (10.8)  2,202 (10.0)  2,072 (10.8)  3,369 (11.5)  
Stomach 4,677 (6.6)  1,631 (7.4)  1,344 (7.0)  1,702 (5.8)  
Liver and intrahepatic bile ducts 3,390 (4.8)  944 (4.3)  933 (4.9)  1,513 (5.2)  
Colon and rectum 3,355 (4.8)  907 (4.1)  915 (4.8)  1,533 (5.2)  
Lymphoid, hematopoietic 1,323 (1.9)  340 (1.5)  352 (1.8)  631 (2.1)  
Other 9,785 (13.9)  2,855 (13.0)  2,679 (14.0)  4,251 (14.5)  
Circulatory disease 30,336 (43.0)  10,200 (46.3)  8,289 (43.3)  11,847 (40.4)  
Cardiovascular 13,858 (19.7)  4,039 (18.3)  3,874 (20.2)  5,945 (20.3)  
Cerebrovascular 15,798 (22.4)  5,959 (27.0)  4,214 (22.0)  5,625 (19.2)  
Other 680 (1.0)  202 (0.9)  201 (1.1)  277 (0.9)  
Respiratory disease 10,012 (14.2)  2,953 (13.4)  2,551 (13.3)  4,508 (15.4)  
CLRD 4,623 (6.6)  1,770 (8.0)  1,214 (6.3)  1,639 (5.6)  
Pneumonia 3,556 (5.0)  756 (3.4)  845 (4.4)  1,955 (6.7)  
Other 1,833 (2.6)  427 (1.9)  492 (2.6)  914 (3.1)  
Abbreviation: SD, standard deviation; IQR, interquartile range; CLRD, chronic lower respiratory disease 
a Chi-square test             
b Analysis of variance test 
c Kruskal-Wallis Test 
d Causes of death prepared by Statistics Korea was linked to KNHIS database 
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2. Legally high-risk LST 
 
During the study period, 7,809 (11.1%) and 8,479 (12.0%) decedents were 
provided with CPR within their last 30 and 180 days of life, respectively (Table 4). 
The proportions of decedents who were provided MV were 16.8% and 20.9% 
within their last 30 and 180 days of life, respectively. Both CPR and MV were 
most likely to be administered to the study decedents during the conflicting period 
of physicians’ legal defensiveness. 
During the study period, 50,129 (71.1%) and 56,822 (80.6%) decedents were 
admitted to hospitals and 13.7% of the decedents were admitted within their last 
30 and 180 days of life, respectively (Table 4). The average hospital days of the 
study decedents were 13.7 and 43.3 days during their last 30 and 180 days of life, 
respectively. Unlike CPR and MV, both the risk of hospital admission and per 
capita hospital days were highest during the relieving period. 
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Table 4 LST-related outcomes for elderly decedents according to the period of physician's legal instability on life-sustaining 
treatment 
   Physicians' legal defensiveness  
Outcomes 
Entire period Increasing period Conflicting period Relieving period  
(2003-2013) (2003–2006) (2007–2009) (2010–2013) P value 
Decedents 70,521  22,032  19,135  29,354   
Legally high-risk LST          
Cardiopulmonary resuscitation          
Last 30 days of life (A) 7,809 (11.1) 2,202 (10.0) 2,314 (12.1) 3,293 (11.2) <0.001a 
Last 180 days of life (B) 8,470 (12.0) 2,434 (11.0) 2,503 (13.1) 3,533 (12.0) <0.001a 
Mechanical ventilation          
Last 30 days of life (A) 11,863 (16.8) 3,515 (16.0) 3,445 (18.0) 4,903 (16.7) <0.001a 
Last 180 days of life (B) 14,734 (20.9) 4,402 (20.0) 4,211 (22.0) 6,121 (20.9) <0.001a 
Outcome control          
Hospital admission          
Last 30 days of life (A) 50,129 (71.1) 12,342 (56.0) 14,365 (75.1) 23,422 (79.8) <0.001a 
Last 180 days of life (B) 56,822 (80.6) 15,302 (69.5) 16,064 (84.0) 25,456 (86.7) <0.001a 
Per capita hospital days [mean, (SD)]          
Last 30 days of life (A) 13.7 (13.1) 9.1 (11.4) 14.8 (13.1) 16.5 (13.3) <0.001bc 
Last 180 days of life (B) 43.3 (53.9) 25.9 (38.9) 46.8 (54.9) 54.1 (59.4) <0.001bc 
Abbreviation: LST, life-sustaining treatment; SD, standard deviation; 
Unit: number (percent) 
a Chi-square test 
b Analysis of variance test 
c Kruskal-Wallis Test 
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Figure 3 shows the trends in level of legally high-risk CPR and MV, and control 
outcome hospital admission and per capital hospital days. In these unadjusted and 
descriptive time series, all four outcomes had been increasing during the 
increasing period of physicians’ legal defensiveness. However, during the 
conflicting period, the trends of outcomes showed different patterns between the 
four study outcomes. During the conflicting period, the risks of receiving CPR 
and MV did not increase but did maintain their levels. Following the conflicting 
period, during the relieving period, the risk of receiving CPR has maintained its 
level. In particular, the risk of receiving MV showed a slightly decreasing pattern 
during the relieving period.  
In contrast, the risk of hospital admission and per capita hospital days increased 
during the conflicting period. This increasing pattern continued during the 
relieving period.  
In summary, while the level of control outcomes increased during the entire 
study period, legally high-risk LSTs stopped increasing during the conflicting 
period and remained steady or decreased during the relieving period.  
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Figure 3 Trends in level of outcomes for elderly decedents with cancer, circulatory, and respiratory diseases 
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Table 5 shows the multivariable adjusted trends and changes in outcomes 
during the last 30 days of life for decedents with cancer, circulatory, or respiratory 
diseases according to the period of physicians’ legal defensiveness toward LST. 
The risk of receiving CPR during last 30 days of life increased 11.9% per year 
(AIR 1.119, 95% CI 1.082-1.158) during the period of increasing legal 
defensiveness. At the time of the first break point in the first quarter of 2007, the 
risk of receiving CPR during the last 30 days of life showed no statistically 
significant change (RR [rate ratio] 1.058, 95% CI 0.953–1.174) and thereafter had 
decreased 6.1% per year (AIR 0.939, 95% CI 0.899–0.981) during the conflicting 
period. At the time of the second break point in the first quarter of 2010, the risk 
of receiving MV during the last 30 days of life showed no statistically significant 
change (RR 1.031, 95% CI 0.931–1.143) and maintained its level (AIR 1.009, 95% 
CI 0.982–1.038) during the relieving period. 
The risk of receiving MV during the last 30 days of life increased 8.3% per year 
(AIR 1.083, 95% CI 1.055–1.112) during the period of increasing legal 
defensiveness. At the time of the first break point in the first quarter of 2007, the 
risk of receiving MV during the last 30 days of life showed no statistically 
significant change (RR [rate ratio] 0.961, 95% CI 0.884–1.044) and maintained its 
level (AIR 1.017, 95% CI 0.982–1.053) during the conflicting period. At the time 
of the second break point in the first quarter of 2010, the risk of receiving MV 
during the last 30 days of life decreased 8.7% (RR [rate ratio] 0.913, 95% CI 
0.843–0.990) and maintained its level (AIR 1.000, 95% CI 0.978–1.022) during 
the relieving period. 
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In contrast to the observed patterns in legally high-risk LSTs, the outcome 
controls showed continuously increasing patterns. The risk of hospital admission 
during the last 30 days of life increased 12.3% (AIR 1.123, 95% CI 1.111–1.134), 
3.6% (AIR 1.036, 95% CI 1.027–1.046), and 1.1% (AIR 1.011, 95% CI 1.006–
1.016) during the first, second, and last period, respectively. The risk of hospital 
admission decreased 2.9% (RR 0.971, 95% CI 0.946–0.997) and 3.3% (RR 0.967, 
95% CI 0.948–0.986) at the time of the first and the second breakpoints. 
Per capita hospital days during last 30 days of life increased 20.5% (AIR 1.205, 
95% CI 1.188–1.223), 4.9% (AIR 1.049, 95% CI 1.034–1.065), and 12.3% (AIR 
1.023, 95% CI 1.015–1.032) during the first, second, and last period, respectively. 
Per capita hospital days did not change (RR 1.002, 95% CI 0.964–1.041) and 
decreased 2.9% (RR 0.971, 95% CI 0.941–1.002) at the time of the first and the 
second breakpoints. 
Table 6 shows the trends and changes in outcomes during last 180 days of life. 
The trends and changes of outcomes were similar during the last 30 and 180 days 
of life. However, unlike the statistically significant decrease in the risk of 
receiving MV during the last 30 days of life at the time of the second break point, 
the risk of receiving MV during the last 180 days of life decreased 5.5% but the 
change was not statistically significant (RR 0.945, 95% CI 0.881–1.014, P=0.117). 
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Table 5 Trend and changes in outcomes during last 30 days of life for elderly decedents according to the period of physicians' 
legal defensiveness toward life-sustaining treatment 
Outcomes Annual increasing rate (AIR)  Ratio of AIR  Level change at break points 
(During last 30 days of life) AIR 95% CI P value  RR
a 95% CI P value  LR
b 95% CI P value 
Legally high-risk LST               
Cardiopulmonary resuscitation               
Increasing period 1.119 1.082 1.158 <0.001  1.000     1.000    
Conflicting period 0.939 0.899 0.981 0.005  0.839 0.795 0.886 <0.001  1.058 0.953 1.174 0.292 
Relieving period 1.009 0.982 1.038 0.520  0.902 0.863 0.942 <0.001  1.031 0.931 1.143 0.554 
Mechanical ventilation               
Increasing period 1.083 1.055 1.112 <0.001  1.000     1.000    
Conflicting period 1.017 0.982 1.053 0.338  0.939 0.900 0.980 0.004  0.961 0.884 1.044 0.342 
Relieving period 1.000 0.978 1.022 0.980  0.923 0.892 0.955 <0.001  0.913 0.843 0.990 0.027 
Outcome control               
Hospital admission               
Increasing period 1.123 1.111 1.134 <0.001  1.000     1.000    
Conflicting period 1.036 1.027 1.046 <0.001  0.923 0.911 0.936 <0.001  0.971 0.946 0.997 0.027 
Relieving period 1.011 1.006 1.016 <0.001  0.901 0.891 0.911 <0.001  0.967 0.948 0.986 <0.001 
Per capita hospital days               
Increasing period 1.205 1.188 1.223 <0.001  1.000     1.000    
Second period 1.049 1.034 1.065 <0.001  0.871 0.853 0.889 <0.001  1.002 0.964 1.041 0.927 
Relieving period 1.023 1.015 1.032 <0.001  0.849 0.836 0.863 <0.001  0.971 0.941 1.002 0.064 
Abbreviations: LST, life-sustaining treatment; CI, confidence interval; RRa , rate ratio; LRb , level ratio 
Adjusted for age in years as continuous variable, sex, type of national health insurance, residential area, household income level, the Charlson Comorbidity 
Score as continuous variable, disability, quarter of year at death, cause of death. 
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Table 6 Trend and changes in outcomes during last 180 days of life for elderly decedents according to the period of physicians' 
legal defensiveness toward life-sustaining treatment 
Outcomes Annual increasing rate (AIR)  Ratio of AIR  Level change at break points 
(During last 180 days of life) AIR 95% CI P value  RR
a 95% CI P value  LR
b 95% CI P value 
Legally high-risk LST               
Cardiopulmonary resuscitation               
Increasing period 1.122 1.086 1.159 <0.001  1.000     1.000    
Conflicting period 0.927 0.889 0.966 <0.001  0.826 0.784 0.870 <0.001  1.047 0.949 1.156 0.361 
Relieving period 1.007 0.980 1.034 0.625  0.897 0.861 0.935 <0.001  1.048 0.950 1.157 0.349 
Mechanical ventilation               
Increasing period 1.070 1.046 1.095 <0.001  1.000     1.000    
Conflicting period 1.013 0.982 1.044 0.425  0.947 0.912 0.983 0.004  0.960 0.892 1.032 0.267 
Relieving period 0.995 0.976 1.015 0.628  0.930 0.903 0.958 <0.001  0.945 0.881 1.014 0.117 
Outcome control               
Hospital admission               
Increasing period 1.080 1.072 1.088 <0.001  1.000     1.000    
Conflicting period 1.022 1.015 1.029 <0.001  0.946 0.937 0.956 <0.001  0.967 0.948 0.986 <0.001 
Relieving period 1.006 1.002 1.010 0.003  0.931 0.924 0.939 <0.001  0.973 0.959 0.988 <0.001 
Per capita hospital days               
Increasing period 1.225 1.204 1.247 <0.001  1.000     1.000    
Conflicting period 1.074 1.053 1.094 <0.001  0.876 0.854 0.899 <0.001  1.043 0.993 1.096 0.093 
Relieving period 1.036 1.025 1.047 <0.001  0.845 0.828 0.863 <0.001  0.952 0.912 0.993 0.021 
Abbreviations: LST, life-sustaining treatment; CI, confidence interval; RRa , rate ratio; LRb , level ratio 
Adjusted for age in years as continuous variable, sex, type of national health insurance, residential area, household income level, the Charlson Comorbidity 
Score as continuous variable, disability, quarter of year at death, cause of death. 
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3. Subgroup analyses 
 
During the study period, 1,599 (5.3%) decedents with cancer, 4,910 (16.2%) 
decedents with circulatory disease, and 1,300 (13.0%) with respiratory disease 
received CPR within their last 30 days of life (Table 7). The risk of receiving MV 
during their last 30 days of life were 8.7%, 22.2%, and 25.0% among decedents 
with cancer, circulatory, and respiratory diseases, respectively. Similar to the 
results in the main analysis, among all three causes of death, both CPR and MV 
were most likely to be administered to the study decedents during the conflicting 
period of physicians’ legal defensiveness. 
During the study period, 24,129 (80.0%) decedents with cancer, 18,629 (61.4%) 
decedents with circulatory disease, and 7,371 (73.6%) decedents with respiratory 
disease were admitted to hospitals (Table 7). The per capita hospital days were 
15.7 days, 11.6 days, and 14.2 days among decedents with cancer, circulatory, and 
respiratory diseases, respectively. Similar to the results of the main analysis, 
among all the three causes of death, unlike CPR and MV, both the risk of hospital 
admission and per capita hospital days were highest during the relieving period. 
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Table 7 Level of outcomes during last 30 days of life for elderly decedents according to the causes of death and the period of 
physicians' legal defensiveness toward life-sustaining treatment 
Outcomes   Physicians' legal defensiveness  
(During last 30 days of life) 
Entire period Increasing period Conflicting period Relieving period  
(2003-2013) (2003–2006) (2007–2009) (2010–2013) P value 
Legally high-risk LST          
Cardiopulmonary resuscitation          
Cancer 1,599 (5.3) 460 (5.2) 476 (5.7) 663 (5.1) 0.108 
Circulatory disease 4,910 (16.2) 1,380 (13.5) 1,452 (17.5) 2,078 (17.5) <0.001a 
Respiratory disease 1,300 (13.0) 362 (12.3) 386 (15.1) 552 (12.2) 0.001 
Mechanical ventilation          
Cancer 2,629 (8.7) 788 (8.9) 752 (9.1) 1,089 (8.4) 0.180 
Circulatory disease 6,734 (22.2) 2,088 (20.5) 1,983 (23.9) 2,663 (22.5) <0.001a 
Respiratory disease 2,500 (25.0) 639 (21.6) 710 (27.8) 1,151 (25.5) <0.001a 
Outcome control          
Hospital admission          
Cancer 24,129 (80.0) 5,877 (66.2) 6,855 (82.6) 11,397 (87.7) <0.001a 
Circulatory disease 18,629 (61.4) 4,826 (47.3) 5,491 (66.2) 8,312 (70.2) <0.001a 
Respiratory disease 7,371 (73.6) 1,639 (55.5) 2,019 (79.1) 3,713 (82.4) <0.001a 
Per capita hospital days [mean, (SD)]          
Cancer 15.7 (12.2) 11.3 (11.6) 16.3 (11.9) 18.3 (11.9) <0.001bc 
Circulatory disease 11.6 (13.4) 7.2 (10.8) 13.0 (13.8) 14.5 (14.1) <0.001bc 
Respiratory disease 14.2 (13.6) 9.0 (11.5) 15.5 (13.5) 16.9 (13.9) <0.001bc 
Abbreviation: LST, life-sustaining treatment; SD, standard deviation 
Unit: number (percent) 
a Chi-square test; b Analysis of variance test; c Kruskal-Wallis Test 
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Figures 6, 7, and 8 represent the unadjusted and descriptive time series trends in 
the level of outcomes during the last 30 days of life among decedents with cancer, 
circulatory, and respiratory diseases, respectively. Although the patterns of time 
series were similar to the main results, each cause of death showed somewhat 
different trends and changes. The levels of control outcomes among all three 
causes of death had been increasing during the entire study period. 
The risk of receiving CPR and MV had been increasing during the increasing 
period of physicians’ legal defensiveness regardless of the cause of death, 
although the magnitude of increase was relatively low among the decedents with 
cancer. During the conflicting period, the risks of receiving CPR and MV did not 
increased but instead maintained their levels. In particular, among decedents with 
cancer, noticeably decreased levels of CPR and MV were observed around the 
time of the Grandma Kim case in 2009. Moreover, the level of CPR and MV 
seems to start to decrease in the conflicting period. 
In particular, the risk of receiving MV showed a marked decrease during the 
relieving period. Among decedents with cancer, the level seemed to be lowered 
from the time of the Grandma Kim case but thereafter remained constant. During 
the relieving period, a decreasing trend of the risk of receiving MV was observed 
among decedents with respiratory disease.  
In summary, among decedents with all three causes of death, while the level of 
control outcomes has been increasing during the entire study period, legally 
high-risk LSTs stopped increasing during the conflicting period and remained 
steady or decreased during the relieving period. 
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Figure 4 Trends in level of outcomes for elderly decedents with cancer
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Figure 5 Trends in level of outcomes for elderly decedents with circulatory disease
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Figure 6 Trends in level of outcomes for elderly decedents with respiratory disease
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Tables 8, 9, and 10 represent the multivariable adjusted trends in outcomes 
during the last 30 days of life among decedents with cancer, circulatory, and 
respiratory diseases, respectively, according to the period of physicians’ legal 
defensiveness towards LST. Although the patterns of time series were similar to 
the main results, each cause of death showed somewhat different trends and 
changes. 
Among decedents with cancer, although not statistically significant, the risk of 
receiving CPR had increased 6.8% per year (AIR 1.068, 95% CI 0.988–1.155) 
during the period of increasing legal defensiveness (Table 8). The risk of receiving 
MV showed no statistically significant change during the entire study period. The 
level of control outcomes showed similar patterns to the main results.  
Among decedents with circulatory disease, except for MV which had increased 
during the conflicting period (AIR 1.055, 95% CI 1.009–1.104), the trends of 
outcomes were similar to the results of the main analysis (Table 9). A noteworthy 
feature was that at the second breakpoint the risk of receiving MV decreased 14.1% 
(RR 0.859, 95% CI 0.773–0.954) and thereafter the level was maintained during 
the relieving period. 
Among decedents with respiratory disease, the risk of receiving MV had 
decreased 5.3% per year (AIR 0.947, 95% CI 0.906–0.990) during the relieving 
period (Table 10). Other results were similar to the main analysis. 
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Table 8 Trend and changes in outcomes during last 30 days of life for decedents with cancer according to the period of 
physicians' legal defensiveness toward life-sustaining treatment 
Decedents with cancer Annual increasing rate (AIR)  Ratio of AIR  Level change at break points 
(During last 30 days of life) AIR 95% CI P value  RR
a 95% CI P value  LR
b 95% CI P value 
Legally high-risk LST               
Cardiopulmonary resuscitation               
Increasing period 1.068 0.988 1.155 0.100  1.000     1.000    
Conflicting period 0.810 0.732 0.896 <0.001  0.759 0.669 0.861 <0.001  1.326 1.046 1.682 0.020 
Relieving period 0.989 0.926 1.056 0.736  0.926 0.837 1.025 0.136  1.296 1.013 1.656 0.039 
Mechanical ventilation               
Increasing period 1.032 0.973 1.094 0.292  1.000     1.000    
Conflicting period 0.952 0.879 1.031 0.225  0.922 0.836 1.017 0.106  1.063 0.881 1.283 0.521 
Relieving period 1.027 0.978 1.080 0.289  0.996 0.923 1.074 0.907  0.959 0.796 1.155 0.657 
Outcome control               
Hospital admission               
Increasing period 1.116 1.102 1.131 <0.001  1.000     1.000    
Conflicting period 1.023 1.011 1.035 <0.001  0.917 0.901 0.933 <0.001  0.951 0.921 0.982 0.002 
Relieving period 1.009 1.004 1.015 <0.001  0.904 0.892 0.917 <0.001  1.000 0.976 1.024 0.987 
Per capita hospital days               
Increasing period 1.173 1.151 1.195 <0.001  1.000     1.000    
Conflicting period 1.037 1.018 1.056 <0.001  0.884 0.861 0.908 <0.001  0.980 0.933 1.030 0.435 
Relieving period 1.019 1.009 1.029 <0.001  0.869 0.851 0.888 <0.001  1.012 0.973 1.052 0.561 
Abbreviations: LST, life-sustaining treatment; RR, rate ratio; CI, confidence interval; RRa , rate ratio; LRb , level ratio 
Adjusted for age in years as continuous variable, sex, type of national health insurance, residential area, household income level, the Charlson Comorbidity 
Score as continuous variable, disability, quarter of year at death, cause of death. 
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Table 9 Trend and changes in outcomes during last 30 days of life for decedents with circulatory diseases according to the period 
of physicians' legal defensiveness toward life-sustaining treatment 
Decedents with circulatory diseases Annual increasing rate (AIR)  Ratio of AIR  Level change at break points 
(During last 30 days of life) AIR 95% CI P value  RR
a 95% CI P value  LR
b 95% CI P value 
Legally high-risk LST               
Cardiopulmonary resuscitation               
Increasing period 1.113 1.067 1.161 <0.001  1.000     1.000    
Conflicting period 0.991 0.939 1.045 0.737  0.890 0.833 0.952 <0.001  0.997 0.876 1.134 0.960 
Relieving period 1.024 0.990 1.060 0.163  0.920 0.873 0.971 0.002  0.971 0.856 1.100 0.641 
Mechanical ventilation               
Increasing period 1.083 1.047 1.120 <0.001  1.000     1.000    
Conflicting period 1.055 1.009 1.104 0.019  0.975 0.922 1.031 0.371  0.906 0.814 1.008 0.070 
Relieving period 1.008 0.979 1.038 0.586  0.931 0.891 0.973 0.002  0.859 0.773 0.954 0.004 
Outcome control               
Hospital admission               
Increasing period 1.100 1.081 1.120 <0.001  1.000     1.000    
Conflicting period 1.050 1.031 1.069 <0.001  0.954 0.931 0.978 <0.001  1.004 0.956 1.054 0.879 
Relieving period 1.015 1.005 1.026 0.003  0.923 0.905 0.942 <0.001  0.929 0.893 0.966 <0.001 
Per capita hospital days               
Increasing period 1.214 1.184 1.245 <0.001  1.000     1.000    
Conflicting period 1.052 1.025 1.080 <0.001  0.867 0.836 0.898 <0.001  1.044 0.975 1.119 0.220 
Relieving period 1.025 1.010 1.041 0.001  0.845 0.820 0.869 <0.001  0.945 0.892 1.001 0.055 
Abbreviations: LST, life-sustaining treatment; RR, rate ratio; CI, confidence interval; RRa , rate ratio; LRb , level ratio 
Adjusted for age in years as continuous variable, sex, type of national health insurance, residential area, household income level, the Charlson Comorbidity 
Score as continuous variable, disability, quarter of year at death, cause of death. 
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Table 10 Trend and changes in outcomes during last 30 days of life for decedents with respiratory diseases according to the 
period of physicians' legal defensiveness toward life-sustaining treatment 
Decedents with respiratory diseases Annual increasing rate (AIR)  Ratio of AIR  Level change at break points 
(During last 30 days of life) AIR 95% CI P value  RR
a 95% CI P value  LR
b 95% CI P value 
Legally high-risk LST               
Cardiopulmonary resuscitation               
Increasing period 1.199 1.100 1.307 <0.001  1.000     1.000    
Conflicting period 0.910 0.815 1.016 0.095  0.759 0.662 0.871 <0.001  0.989 0.763 1.282 0.932 
Relieving period 0.972 0.906 1.043 0.428  0.811 0.726 0.905 <0.001  0.997 0.771 1.290 0.984 
Mechanical ventilation               
Increasing period 1.127 1.061 1.197 <0.001  1.000     1.000    
Conflicting period 0.974 0.905 1.048 0.479  0.864 0.787 0.949 0.002  1.006 0.839 1.207 0.948 
Relieving period 0.947 0.906 0.990 0.016  0.840 0.780 0.905 <0.001  1.029 0.873 1.214 0.731 
Outcome control               
Hospital admission               
Increasing period 1.178 1.145 1.212 <0.001  1.000     1.000    
Conflicting period 1.038 1.013 1.063 0.003  0.881 0.849 0.913 <0.001  0.932 0.869 1.000 0.050 
Relieving period 1.004 0.992 1.016 0.529  0.852 0.826 0.878 <0.001  0.947 0.902 0.995 0.031 
Per capita hospital days               
Increasing period 1.252 1.203 1.304 <0.001  1.000     1.000    
Conflicting period 1.070 1.028 1.115 0.001  0.855 0.808 0.905 <0.001  0.937 0.840 1.046 0.245 
Relieving period 1.028 1.006 1.050 0.011  0.821 0.785 0.859 <0.001  0.896 0.823 0.975 0.011 
Abbreviations: LST, life-sustaining treatment; RR, rate ratio; CI, confidence interval; RRa , rate ratio; LRb , level ratio 
Adjusted for age in years as continuous variable, sex, type of national health insurance, residential area, household income level, the Charlson Comorbidity 
Score as continuous variable, disability, quarter of year at death, cause of death. 
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4. Sensitivity analyses 
 
(1) Restriction to decedents who were admitted to hospitals 
 
Table 14 represents the results of the sensitivity analysis that was conducted to 
control for the effect of increased medical resources during the study period. The 
study subjects were restricted to the 56,822 decedents who were admitted to 
hospitals during their last 180 days of life. During the study period, 6,199 (10.9%) 
and 6,857 (12.1%) decedents were provided CPR within their last 30 and 180 
days of life, respectively (Table 14). The proportions of decedents who were 
provided MV were 18.9% and 23.9% within their last 30 and 180 days of life, 
respectively. Unlike the main analysis, both CPR and MV were most likely to be 
administered to the study decedents during the increasing period and then 
decreased during the conflicting and relieving period. 
The number of decedents who had admitted to hospitals was the same as those 
of the main results, but the proportions changed to 88.2% and 100% during the 
last 30 and 180 days of life, respectively (Table 14). The average hospital stay 
days of the study decedents were 17.0 and 53.7 days during their last 30 and 180 
days of life, respectively. Unlike CPR and MV, both the risk of hospital admission 
and per capita hospital days were highest during the relieving period. 
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Table 11 Level of outcomes for elderly decedents who admitted to hospitals during last 180 days of life according to the period 
of physicians' legal defensiveness toward life-sustaining treatment 
Outcomes   Physicians' legal defensiveness  
(Decedents who had admitted to hospitals 
during last 180 days of life) 
Entire period Increasing period Conflicting period Relieving period  
(2003-2013) (2003–2006) (2007–2009) (2010–2013) P value 
Decedents 56,822  15,302  16,064  25,456   
Legally high-risk LST          
Cardiopulmonary resuscitation          
Last 30 days of life (A) 6,199 (10.9) 1,777 (11.6) 1,900 (11.8) 2,522 (9.9) <0.001a 
Last 180 days of life (B) 6,857 (12.1) 2,007 (13.1) 2,089 (13.0) 2,761 (10.8) <0.001a 
Mechanical ventilation          
Last 30 days of life (A) 10,720 (18.9) 3,144 (20.5) 3,142 (19.6) 4,434 (17.4) <0.001a 
Last 180 days of life (B) 13,584 (23.9) 4,026 (26.3) 3,908 (24.3) 5,650 (22.2) <0.001a 
Outcome control          
Hospital admission          
Last 30 days of life (A) 50,129 (88.2) 12,342 (80.7) 14,365 (89.4) 23,422 (92.0) <0.001a 
Last 180 days of life (B) 56,822 (100.0) 15,302 (100.0) 16,064 (100.0) 25,456 (100.0)  
Per capita hospital days [mean, (SD)]          
Last 30 days of life (A) 17.0 (12.5) 13.1 (11.6) 17.6 (12.4) 19.1 (12.4) <0.001bc 
Last 180 days of life (B) 53.7 (55.2) 37.2 (41.9) 55.7 (55.6) 62.4 (59.6) <0.001bc 
Abbreviation: LST, life-sustaining treatment; SD, standard deviation; 
Unit: number (percent) 
a Chi-square test 
b Analysis of variance test 
c Kruskal-Wallis Test 
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Figure 3 shows unadjusted and descriptive time trends in levels of outcomes 
among the decedents who were admitted to hospitals during their last 180 days of 
life. Similar to the main analysis, the level of hospital admissions and the per 
capita hospital days seemed to have increased during the entire study period. 
However, the risks of receiving CPR and MV showed different patterns. 
Graphically, the risks of receiving CPR and MV seemed to have not increased 
during the increasing period of legal defensiveness. However, the level of CPR 
and MV seemed to decrease during the conflicting and relieving periods. In 
particular, a decreasing trend of MV was observed during the relieving period.  
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Figure 7 Trends in level of outcomes for elderly decedents who had admitted to hospitals during last 180 days of life
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Table 5 shows the multivariable adjusted trends and changes in outcomes 
during the last 30 days of life for decedents who were admitted to hospitals during 
their last 180 days of life. In addition to the covariates included in the main 
analysis, the type of medical institution where the decedents were last admitted 
was added to the multivariate Poisson regression model. Unlike the descriptive 
patterns in Figure 7, the risk of receiving CPR and MV during the increasing 
period of legal defensiveness had increased 6.0% (AIR 1.060, 95% CI 1.021–
1.101) and 5.3% (AIR 1.053, 95% CI 1.026–1.082), respectively. The results of 
this segmented regression were similar to the main results although the magnitude 
of the AIRs was smaller. 
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Table 12 Trend and changes in outcomes during last 30 days of life for elderly decedents who admitted to hospitals during last 
180 days of life according to the period of physicians' legal defensiveness toward life-sustaining treatment 
Decedents admitted to hospitals Annual increasing rate (AIR)  Ratio of AIR  Level change at break points 
(During last 30 days of life) AIR 95% CI P value  RR
a 95% CI P value  LR
b 95% CI P value 
Legally high-risk LST               
Cardiopulmonary resuscitation               
Increasing period 1.060 1.021 1.101 0.003  1.000     1.000    
Conflicting period 0.891 0.849 0.935 <0.001  0.840 0.791 0.892 <0.001  1.177 1.049 1.321 0.006 
Relieving period 1.007 0.976 1.039 0.679  0.950 0.904 0.997 0.037  1.045 0.932 1.173 0.450 
Mechanical ventilation               
Increasing period 1.053 1.026 1.082 <0.001  1.000     1.000    
Conflicting period 1.001 0.967 1.035 0.971  0.950 0.910 0.991 0.018  1.053 0.969 1.144 0.226 
Relieving period 0.996 0.975 1.018 0.715  0.946 0.914 0.978 0.001  0.946 0.875 1.024 0.168 
Outcome control               
Hospital admission               
Increasing period 1.033 1.026 1.041 <0.001  1.000     1.000    
Conflicting period 1.012 1.006 1.019 <0.001  0.980 0.971 0.989 <0.001  0.999 0.982 1.017 0.924 
Relieving period 1.004 1.001 1.008 <0.001  0.972 0.965 0.980 <0.001  0.992 0.979 1.006 0.254 
Per capita hospital days [mean, (SD)]               
Increasing period 1.085 1.072 1.099 <0.001  1.000     1.000    
Conflicting period 1.017 1.004 1.029 0.008  0.937 0.921 0.953 <0.001  1.005 0.973 1.038 0.760 
Relieving period 1.012 1.006 1.019 <0.001  0.933 0.920 0.946 <0.001  0.995 0.969 1.022 0.724 
Abbreviations: LST, life-sustaining treatment; CI, confidence interval; RRa , rate ratio; LRb , level ratio 
Adjusted for age in years as continuous variable, sex, type of national health insurance, residential area, household income level, the Charlson Comorbidity 
Score as continuous variable, disability, quarter of year at death, cause of death, type of lastly admitted hospital. 
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(2) Division of the study period into two periods 
 
Table 16 shows the results of the sensitivity analysis in which the study period 
was divided into two distinct periods of the increasing and relieving period at the 
time of the third quarter of 2009. The multivariate adjusted AIRs showed similar 
results to the main analysis across the three periods. The risk of receiving CPR 
and MV had increased during the increasing period of legal defensiveness and 
then maintained their levels during the relieving period. In contrast to the legally 
high-risk LSTs, the risk of hospital admission and per capita hospital days had 
increased during both increasing and relieving periods. 
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Table 13 Trend and changes in outcomes during last 30 days of life for elderly decedents according to the period of physicians' 
legal defensiveness toward life-sustaining treatment 
Outcomes Annual increasing rate (AIR)  Ratio of AIR   Level change at break points 
(During last 30 days of life) AIR 95% CI P value  RR
a 95% CI P value  LR
b 95% CI P value 
Legally high-risk LST               
Cardiopulmonary resuscitation               
Increasing periodc 1.071 1.055 1.087 <.0001  1.000     1.000    
Relieving period 1.013 0.990 1.037 0.276  0.946 0.921 0.972 <.0001  0.819 0.757 0.886 <.0001 
Mechanical ventilation               
Increasing perioda 1.050 1.037 1.062 <.0001  1.000     1.000    
Relieving period 0.988 0.969 1.006 0.186  0.941 0.921 0.962 <.0001  0.909 0.854 0.968 0.003 
Outcome control               
Hospital admission               
Increasing periodc 1.085 1.080 1.089 <.0001  1.000     1.000    
Relieving period 1.008 1.004 1.012 <.0001  0.930 0.924 0.935 <.0001  0.920 0.906 0.935 <.0001 
Per capita hospital days [mean, (SD)]               
Increasing periodc 1.145 1.138 1.152 <.0001  1.000     1.000    
Relieving period 1.020 1.014 1.027 <.0001  0.891 0.883 0.899 <.0001  0.882 0.860 0.904 <.0001 
Abbreviations: LST, life-sustaining treatment; CI, confidence interval; RRa , rate ratio; LRb , level ratio 
Adjusted for age in years as continuous variable, sex, type of national health insurance, residential area, household income level, the Charlson Comorbidity 
Score as continuous variable, disability, quarter of year at death, cause of death. 
c Ended in the second quarter of 2009 when the Supreme Court decision on the Grandma Kim case was made 
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Ⅵ. Discussion 
 
1. Study methods 
 
In this study, LST-related outcomes during the last 30 days of life were assessed 
retrospectively. There have been debates about study design regarding prospective 
and retrospective approaches in the literature98,120-122. Many studies have 
retrospectively assessed the care received by patients in the period leading up to 
death, whereas others have identified patients entering the terminal phase of 
disease and prospectively observed their care forward in time. Each of these 
approaches has its theoretical and practical advantages and disadvantages. In 
prospective studies of end-of-life care, investigators traditionally identify a group 
of subjects who are known to be “dying,” as evidenced by a sentinel event—for 
instance, subjects diagnosed with metastatic cancer, transferred to a long-term 
acute care facility, or admitted to a hospice121. Investigators then observe the care 
that these “dying” subjects receive, usually up to the point of their death. Studies 
that follow this design are termed “cohort studies” because they focus on the 
events that occur after an individual has acquired a particular characteristic that 
makes him or her eligible for the study. Incomplete enrollment of patients is an 
important potential limitation of prospective cohort studies122. In retrospective 
studies of end-of-life care, the cohort consists of decedents. Investigators then 
look back over the time leading up to death to observe end-of-life care120. In 
accordance with epidemiologic principles, these studies are called “case series.” 
Case series focus on events that occur prior to an individual acquiring a particular 
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characteristic that makes him or her eligible for the study121.  
Retrospective designs have several advantages over prospective designs120. 
First, they allow for easy identification of cohorts of relevant patients. In contrast, 
prospectively identifying patients who are approaching the end of life is often not 
feasible, especially from administrative data sources. Second, a retrospective 
approach allows all patients who come to the end of life to be studied, not just a 
nonrandom subset defined by a disease characteristic or event that identifies them 
as dying. The prospective design is best used for research questions about the care 
given to patients who can readily be identified as having a terminal illness. The 
retrospective approach is optimal for asking, “what happens to patients who die 
shortly before death?” Retrospective designs are convenient, generalizable, and 
efficient for evaluating and implementing performance indicators related to 
end-of-life care120. 
In this study, under the inevitable limitations of administrative claims data, 
exact prognostication of dying patients was not feasible. Furthermore, unlike other 
studies investigated end-of-life care among patients with chronic diseases, 
especially cancer, patients with acute diseases such as myocardial infarction and 
bacterial pneumonia were included in this study. Inclusion of patients with acute 
diseases made prognostication more difficult than in other studies. Considering 
the tradeoff between the strengths and limitations of retrospective and prospective 
designs, retrospective observation was chosen as the study design. 
Under the retrospective design, this study could include all decedents including 
those who were not admitted to hospitals, who had not utilized medical services 
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for a long time before death, and those who died in a very short time after disease 
onset. Thus, this study represents all decedents in South Korea. CPR, MV, and 
ICU care could be provided to patients who had not been prognosticated as dying. 
In some patients, these efforts could be not LST but meaningful usual treatment. If 
CPR, MV, and ICU care had been provided as usual treatment but the results were 
death within 30 days, those decedents were included as study subjects. However, 
because the proportion of misclassifications were thought to be fairly constant 
throughout the study period, the effect of a relatively slow change of 
misclassification could be absorbed into the slope change in the segmented 
regression model115. 
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2. Study results 
 
In this study a conceptual framework for legal defensiveness model was 
developed. Based on the conceptual model, whether the decrease of legal 
defensiveness could decrease legally high-risk LSTs (CPR and MV) and whether 
legally high-risk LSTs could decrease earlier than patient-driven control outcomes 
(hospital admission and per capita hospital days) were examined through 
quasi-experimental quantitative analyses under the natural experimental 
circumstances. This mixed approach with legal and medical aspects revealed that 
in general legally high-risk LSTs had increased during the period of increasing 
legal defensiveness, then had decreased during the period of conflicting legal 
defensiveness, and then showed a plateau or decreasing pattern during the period 
of relieving legal defensiveness. In general, control outcomes had increased 
sharply during the period of increasing legal defensiveness, but AIR decreased 
and then the level increased during the period of conflicting legal defensiveness, 
and then AIR were decreased further but the level was increased during the period 
of relieving legal defensiveness. These patterns were repeated in cancer, 
circulatory, and respiratory diseases. In particular, the decrease of LST was 
prominent among decedents with respiratory diseases. 
Although the risk of admission to hospitals and per capita hospital days 
increased throughout the entire study period, the risk of CPR and MV decreased 
or was maintained during the second and third period. Supply-sensitive care such 
as admission to hospitals and per capita hospital days was affected by an increased 
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supply of medical resources such as hospital beds but emergent medical 
procedures such as CPR and MV did not show a similar effect8,123,124. This could 
be interpreted to mean that in spite of the increased supply of medical resources 
the risk of receiving CPR and MV decreased, and this means there would be an 
underestimation of effect size regarding CPR and MV. 
Unfortunately, there is no previous study to compare this study’s results with. 
Some studies reported that tort-law reform limiting physician’s liability decreased 
malpractice pressure among physicians46,52. Other studies reported survey results 
among physicians that defensive medicine is highly prevalent among physicians 
who pay the most for liability insurance53,56. A low level of specific defensive 
cesarean section was reported after comparing rates among counties with different 
liability burdens64. As for East Asian countries, using cross-sectional surveys of 
physicians, it was suggested that over-prescription in Chinese hospitals was driven 
not only by hard economic incentives, but also by physician's motive of avoiding 
disputes with patients54. On reviewing the above articles, it seems that policies 
limiting legal liability against malpractice dispute could decrease legal 
defensiveness toward general medical treatment. Because the consequence of an 
LST-related decision is death of the patient, the defensive attitude of previous 
studies might be lower than that of this study. In the course of LST-related 
decisions, family members of a dying patient play important roles than other 
general medical decisions dealt with in previous studies. Therefore, physicians 
should consider more factors associated with LST-related decisions than with 
other medical decisions. From the fact that the consequence of LST-related death 
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is more serious and family members play a more important role than in other 
general medical decisions, previous studies reporting the low liability of 
physicians associated with low malpractice pressure supports the results of this 
study.  
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3. Limitations and strengths 
 
(1) Limitations 
 
There are several limitations in this study. First, the selection of the point at 
which the time series is divided into three periods is subjective. Whereas the break 
point in the first quarter of 2010 was a relatively clear point where the time series 
was interrupted by a major event such as the Supreme Court judgment for 
Grandma Kim’s case and the death of Gramm Kim, the break point in the first 
quarter of 2007 was a relatively vague point where publically sensational events 
were absent. However, a cirrhosis case which was reported as the first case 
allowed by the prosecution, and debates about death with dignity reported by 
KBS’s Tracking 60 Minutes took place in the second quarter of 2007. The events 
during the second quarter of 2007 were supported by quantitative analysis of 
attention among South Korean people and physicians. To measure the attention of 
South Korean people, a Google trend analytics search was carried out using 
Korean terms meaning the Boramae hospital case, life-sustaining treatment, death 
with dignity, and related terms in South Korea, which tracks the popularity of 
peak searching for this term from 2004 (Appendix 1). We found increasing public 
attention on LST-related terms during the conflicting period of legal instability 
followed by decreasing attention. To measure the attention of physicians, the 
number of news items dealing with the Boramae hospital case, life-sustaining 
treatment, death with dignity, and related terms from the Newspapers of Korea 
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Medical Association were evaluated (Appendix 2). We found increasing 
physician’s attention on LST-related terms during the conflicting period of legal 
instability followed by decreasing attention. In particular, physicians conducting 
withholding or withdrawal of LST are small in number and they are very sensitive 
to news items related to LST. Because the division was based on physician’s 
perceived legal instability, the first quarter of 2007 could be an appropriate break 
point in the time series. Furthermore, two attorney-at-laws with medical doctor 
qualification reviewed LST-related events during the study period and selected the 
two break points as the point where the time series were interrupted.  
Second, there are intrinsic limitations of administrative claims data. Disease 
codes listed in the cohort may not represent participant’s true disease status 
because the code was created to claim health insurance serviced to participants, an 
inherent limitation of insurance databases97. Non-insurance benefits have not been 
included such as cosmetic surgeries and over-the-counter drugs. However, LST 
related benefits have been covered by the NHI and opioid analgesics are not 
over-the-counter drugs in South Korea. Evaluating details of a participant’s 
specific medical treatment is difficult if patients’ insurance claims were made 
under the diagnosis-related-group (DRG) policy. However, in Korea, nearly all 
types of healthcare providers follow the fee-for-service system and the DRG is 
applied only to seven disease groups97 unrelated to LST. Furthermore, the sole 
purpose of constructing the cohort was to provide public health researchers and 
policy makers with representative, useful information regarding citizens’ 
utilization of health insurance and health examinations97.  
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Third, in September 2005 and December 2009 there were benefit expansion 
policies to lower copayments for serious diseases including cancer, cardiac, and 
cerebrovascular diseases125. These two events could give patient side incentives 
for increasing health care utilization by reducing their economic burden. However, 
when focusing on LST and health care utilization of dying patients, the increasing 
trends had existed before the policy and the trend changes near the policy were 
not observed, and thus the effect of benefit expansion policy did not considerably 
influence the validity of this study. Rather, the results of this study might be 
underestimated considering the decreasing trends despite a decreased economic 
burden. Furthermore, many diseased or dying patients were not included in the 
benefit expansion policy. 
Fourth, public discussion about the implementation of a hospice care system 
and palliative care units had been gradually increased after the Boramae hospital 
case and the National Cancer Control Act, and The Ministry of Health and 
Welfare had managed a demonstration project to develop a national health 
insurance service policy for hospice and palliative care from 2009 to 2015126. 
However, during the study period, the recipients of hospice care were limited to 
terminal cancer patients and the number of hospice beds has been remained 
substantially small compared to the number of terminal cancer patients. The 
utilization rate of hospice care has increased 7.3% in 2008 to 12.7% in 2013126,127. 
Because the number of dying patients with cancer is small, and most dying 
patients were not the recipients of hospice care, the effect of hospice care might be 
expected to be small in this study. Furthermore, because accepting hospice care 
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could affect the active LST-related decisions of physicians, a possible decrease of 
LST due to hospice care should be included in decreased LST by reducing the 
legal defensiveness of physicians. 
Fifth, during the study period, the proportion of decedents who died in 
long-term care hospitals has increased approximately coinciding with the increase 
in the numbers of long-term care hospital beds. Moreover, beginning in 2008, 
reimbursement for long-term care hospitals changed from fee-for-service to a per 
diem fixed payment system. Except for admission and ICU care, exact 
identification of specific procedures such as CPR and MV conducted during 
long-term care hospital care could be difficult since 2008. However, 
fee-for-service reimbursement has been applied to patients discharged within 6 
days, pneumonia patients, septicemia patients, patients in the ICU, and patients 
within the post-operation period111. CPR and MV reimbursed by fee-for-service 
could be detected and these procedures are provided to seriously ill patients 
included with the exception of cases of per diem reimbursement, and therefore the 
effect of per diem reimbursement on the identification of MV could be 
minimalized. Because transfer of dying patients from acute care hospitals to 
long-term care hospitals could be actively correlated with LST-related decisions to 
not perform LST, the increasing numbers of deaths in long-term care hospitals 
should be interpreted as active LST-related decisions. In addition, legal instability 
is also present among physicians in long-term care hospitals. Legal anxieties 
during end-of-life care in nursing homes in the US have been reported in articles 
with a legal perspective45.  
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Whereas the proportion of decedents in extra-hospital place has decreased 
continuously, the proportion of decedents in long-term care hospitals has 
increased during the study period. This opposing trend might suggest a transition 
of death place from decedents who might have died extra-hospital to long-term 
hospitals. Death in extra-hospital means no LST, and the considerable proportion 
of deaths in long-term care hospitals should be interpreted as the results of active 
LST-related decisions of physicians. Recall that a death after discharge from a 
hospital was the reason for the Boramae hospital case. 
Sixth, the measured outcomes were mainly withholding of LST. Due to the 
absence of medical chart information, differentiation between withholding and 
withdrawal of LST was not feasible. Outcome variables measured by the presence 
within last 30 days of life are a surrogate for withholding of LST. Although some 
dying patients receiving LST might experience withdrawal of LST at some point 
before death, withdrawal of LST in South Korea has been extremely rare since the 
Boramae hospital case. Future studies should investigate withdrawal of LST using 
clinical data from patients receiving LST. 
Seventh, the roles of the patient side during LST-related decision making were 
not considered thoroughly. In the legal defensive model, the effect of patient side 
factors was incorporated into the doctor-patient relationship and their influence on 
physician’s legal defensiveness and preference for LST. Characteristics of family 
members were not considered due to absence of information. However, factors 
such as sex, age, and cause of death that were reported to be associated with 
patient’s preference for LST were adjusted in multivariate regression 
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models15,19,128-130.  
 
(2) Strengths 
 
Despite the above limitations, this study has some strengths. First, the 
NHIS-NSEC database contains representative population-based cohort data, 
which is a major strength as it ensures its applicability in research when 
evaluating the effects of medical practice on health outcomes. Moreover, the data 
are large-scale, extensive, and stable because it was constructed based on 
nationwide health insurance data generated by a monopolistic national health 
insurer. The NHIS-NSEC was constructed by the method of 10% simple random 
sampling from Korean people aged 60 or over in 2002. Therefore, dying patients 
not admitted to hospitals were also included in this study.  
Second, a quasi-experimental study design was used as a quantitative analysis 
method. The interrupted time series design is a strong, quasi-experimental 
approach for evaluating longitudinal effects of interventions, and this design is 
robust despite the lack of randomization, because multiple pre- and 
post-intervention observations allow the detection of and accounting for time 
trends that are unrelated to the intervention131,132. Its main advantage over 
alternative approaches is that it can make full use of the longitudinal nature of the 
data and account for pre-intervention trends105. This design is particularly useful 
when “natural experiments” in real word settings occur—for example, when a 
health policy change comes into effect105. The nature of the natural experiment of 
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this study comes from fact that the period of rising legal instability was the first 
intervention and the period of conflicting legal instability was the second 
intervention in this study. Several previous studies have used a 
difference-in-difference study design comparing only 2 time points to investigate 
net policy impacts on outcomes or used segmented regression with less than 10 
time points52,63. The time points were too small to capture baseline trends and 
their changes in those previous studies. Using 44 time points, this study captured 
trend changes more robustly. 
Third, to the author’s best knowledge, this study is the first study in many 
aspects. First, this is the first study that investigated the effect of legal 
defensiveness on the LST-related decision by quantitative analysis using 
nationally representative claims data. There are several studies that investigated 
the effect of tort-law reform on malpractice claims or costs48,52. Studies 
investigating specific medical procedure such as cesarean section are very scarce64. 
However, none of previous studies directly investigated LST-related procedures 
and defensive medicine. Instead of surveys56,133 or interviews65 of physicians, this 
study used claims data to identify specific clinical procedures and health care 
utilization. Second, this is the first study to provide descriptive statistics for the 
level of LST-related outcomes serially in South Korea. Third, this is the first study 
that divided a time series into three periods according to a conceptual framework 
of legal defensiveness model in South Korea. Fourth, this is the first study that 
integrated a legal conceptual approach and medical quantitative approach into one 
study design in South Korea. 
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Ⅶ. Conclusion and Policy Implication 
 
This study provides evidence that physicians’ legal defensiveness toward 
forgoing LST contributes to administering LST and if physician’s legal 
defensiveness is decreased, then defensive LST is also decreased. However, legal 
defensiveness is still considerable and the level of LST could be decreased further. 
There are some policy implications to alleviate physicians’ legal defensiveness 
in terms of a physician-side approach. First, the scope of target patients in the LST 
Act should be broadened to diminish medical uncertainty in the process of 
determining medical futileness of LST. Currently, only patients in the 
irrecoverable death stage can exercise their constitutional right to refuse unwanted 
LST. A patient’s constitutional right to refuse LST should be protected more 
comprehensively. Second, a procedural requirement for a legal immunity of 
physicians should be concretized. Clauses regarding physicians’ legal immunity 
were not provided in the LST Act. Physicians should be able to discontinue futile 
LST with procedural legitimacy from patients who met the substantive 
requirement. The hospital ethics committee could play an important role by 
reducing medical and legal uncertainty. Third, physicians should be informed of 
legal knowledge related to forgoing LST. Ignorance or misunderstanding of the 
law should be avoided. 
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국문초록 
 
법방어적 태도에 의하여 유도된 연명치료: 
자연유사실험 결과 
 
배경: 무의미한 연명치료에 대한 지대한 관심에도 불구하고 의사의 법적 불안
정성의 감소가 연명치료의 감소로 이어질 수 있는지에 관하여 알려진 바가 거
의 없다. 연명치료 중단 및 보류에 대한 법방어적 태도를 중심으로, 의사의 법
방어적 태도가 감소할 경우 연명치료의 시행이 감소하는지를 두 개의 판결에 
의하여 형성된 자연실험적 상황에 대한 유사실험적 연구설계를 통하여 분석하
였다. 
 
대상 및 방법: 방어의료 및 법방어적 태도에 관한 선행연구를 종합하여 법방
적적 태도 모형을 위한 개념적 틀을 제시하고, 이로부터 계량적 분석을 위한 
연구설계를 도출하였다. 연구자료는 2002년에 60세 이상이었던 노인 588,147명
으로 구성된 국민건강보험공단 노인코호트를 사용하였다. 노인코호트로부터 
2003년부터 2013년 사이에 암, 순환기 및 호흡기 질환으로 사망한 70세에서 
89세까지의 노인 73,096명을 연구대상자로 선정하였다. 2003년부터 2013년까지 
년 4분기로 나누어 시계열을 구축하였으며 연구기간은 의사의 연명치료 중단 
및 보류에 대한 법방어적 태도의 수준에 따라 상승기, 갈등기, 완화기의 세 시
기로 구분하였다. 주로 의사에 의하여 시행여부가 결정되는 법적 고위험 연명
치료(심폐소생술, 기계환기)의 사망 전 30일 내 시행수준 및 변화를 분기별로 
산출하여 세 시기 사이에 비교하였다. 환자측의 의사결정이 큰 역할을 하는 
병원입원 여부 및 재원일수를 대조를 위한 결과변수로 사용하였다. 분절적 회
귀모형을 통한 중도절단 시계열분석을 위하여 포아송 분포 및 강건표준오차를 
사용한 일반화선형모델을 사용하였다. 시기별로 연증가율을 추정하고 각 시기 
117 
 
사이의 연증가율의 비를 95퍼센트 신뢰구간과 함께 추정하였다. 
 
결과: 사망 전 30일 내에 7,809명(11.1%)의 대상자가 심폐소생술을, 11,863명
(16.8%)의 대상자가 기계환기를 시행 받았다. 사망 전 30일 내에 심폐소생술을 
시행 받을 위험은 법방어적 태도의 상승기에 연평균 11.9%(AIR 1.119, 95% CI 
1.082-1.158) 증가하다가 갈등기에는 매년 6.1%(AIR 0.939, 95% CI 0.899-0.981) 
감소하였으며 완화기에는 그 수준을 유지하였다(RR 1.009, 95% CI 0.982-
1.038). 사망 전 30일 내에 기계환기를 시행 받을 위험은 상승기에 연평균 
8.3%(AIR 1.083, 95% CI 1.055-1.112) 증가하다가 갈등기(AIR 1.017, 95% CI 
0.982-1.053)와 완화기 (AIR 1.000, 95% CI 0.978-1.022)에는 그 수준을 유지하
였다. 이에 비하여, 비록 갈등기와 완화기의 연증가율이 상승기보다 작을지라
도 병원에 입원할 위험(12.3%, 3.6%, 1.1%) 및 재원기간(20.5%, 4.9%, 2.3%)은 
세 시기 모두에서 증가하였다. 
 
결론: 대한민국에서 의사의 연명치료 중단에 대한 법방어적 태도가 연명치료
의 제공에 기여하고 있으며, 의사의 법방어적 태도가 완화될 경우 방어적 연
명치료가 감소할 수 있다. 법방어적 태도는 상당 정도 남아 있으며 연명치료
의 시행이 더욱 감소할 필요가 있다. 이를 위하여 의사의 법적 불안정성을 감
소시킬 수 있는 정책이 시행되어야 한다. 
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